<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2017.01058</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Transcriptional Alterations of Virulence-Associated Genes in Extended Spectrum Beta-Lactamase (ESBL)-Producing Uropathogenic <italic>Escherichia coli</italic> during Morphologic Transitions Induced by Ineffective Antibiotics</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Demirel</surname> <given-names>Isak</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/426471/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Rangel</surname> <given-names>Ignacio</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Petersson</surname> <given-names>Ulrika</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Persson</surname> <given-names>Katarina</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kruse</surname> <given-names>Robert</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x0002A;</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>School of Medical Sciences, &#x000D6;rebro University</institution> <country>&#x000D6;rebro, Sweden</country></aff>
<aff id="aff2"><sup>2</sup><institution>Faculty of Medicine and Health, Inflammatory Response and Infection Susceptibility Centre, &#x000D6;rebro University</institution> <country>&#x000D6;rebro, Sweden</country></aff>
<aff id="aff3"><sup>3</sup><institution>Faculty of Medicine and Health, Nutrition-Gut-Brain Interactions Research Centre, &#x000D6;rebro University</institution> <country>&#x000D6;rebro, Sweden</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Clinical Research Laboratory, Faculty of Medicine and Health, &#x000D6;rebro University</institution> <country>&#x000D6;rebro, Sweden</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Jorge Blanco, Universidade de Santiago de Compostela, Spain</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Miguel A. De la Cruz, Instituto Mexicano del Seguro Social, Mexico; Juan Marzoa, Universidade de Santiago de Compostela, Spain</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: Robert Kruse <email>robert.kruse&#x00040;oru.se</email></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Infectious Diseases, a section of the journal Frontiers in Microbiology</p></fn></author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>1058</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>03</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>05</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Demirel, Rangel, Petersson, Persson and Kruse.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Demirel, Rangel, Petersson, Persson and Kruse</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>It is known that an ineffective antibiotic treatment can induce morphological shifts in uropathogenic <italic>Escherichia coli</italic> (UPEC) but the virulence properties during these shifts remain to be studied. The present study examines changes in global gene expression patterns and in virulence factor-associated genes in an extended spectrum beta-lactamase (ESBL)-producing UPEC (ESBL019) during the morphologic transitions induced by an ineffective antibiotic and in the presence of human primary bladder epithelial cells. Microarray results showed that the different morphological states of ESBL019 had significant transcriptional alterations of a large number of genes (Transition; 7%, Filamentation; 32%, and Reverted 19% of the entities on the array). All three morphological states of ESBL019 were associated with a decreased energy metabolism, altered iron acquisition systems and altered adhesion expression. In addition, genes associated with LPS synthesis and bacterial motility was also altered in all the morphological states. Furthermore, the transition state induced a significantly higher release of TNF-&#x003B1; from bladder epithelial cells compared to all other morphologies, while the reverted state was unable to induce TNF-&#x003B1; release. Our findings show that the morphological shifts induced by ineffective antibiotics are associated with significant transcriptional virulence alterations in ESBL-producing UPEC, which may affect survival and persistence in the urinary tract.</p>
</abstract>
<kwd-group>
<kwd>filamentation</kwd>
<kwd>extended-spectrum &#x003B2;-lactamase</kwd>
<kwd>uropathogenic <italic>Escherichia coli</italic></kwd>
<kwd>ineffective antibiotics</kwd>
<kwd>morphological plasticity</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="38"/>
<page-count count="15"/>
<word-count count="8659"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Urinary tract infections (UTIs) are one of the most common bacterial infections. UTI is especially common in women as nearly half of all women will be infected during their lifetime (Foxman, <xref ref-type="bibr" rid="B14">2003</xref>). The vast majority of all urinary tract infections are caused by uropathogenic <italic>Escherichia coli</italic> (UPEC), accounting for approximately 80% of community-acquired symptomatic UTI and approximately 25% of the nosocomial infections (Ronald, <xref ref-type="bibr" rid="B29">2003</xref>). UPEC isolates have been shown to express an array of virulence factors like adhesins (such as P- and type-1 fimbriae), toxins (&#x003B1;-hemolysin), lipopolysaccharide (LPS), capsular, siderophores (iron scavenger system) and TcpC to evade the host defenses and colonize the urinary tract (Bower et al., <xref ref-type="bibr" rid="B5">2005</xref>; Yadav et al., <xref ref-type="bibr" rid="B38">2010</xref>).</p>
<p>During UTI, UPEC may invade the urothelial cells where they can replicate and form biofilm-like intracellular bacterial communities (IBCs) (Anderson et al., <xref ref-type="bibr" rid="B2">2003</xref>). Likewise, after the resolution of an active infection non-replicating bacteria can remain within vesicles in deeper layers of the urothelium as quiescent intracellular reservoirs (QIRs) (Mysorekar and Hultgren, <xref ref-type="bibr" rid="B25">2006</xref>). These QIRs can remain quiescent for several months without eliciting an inflammatory response. The intracellular niche not only protects the bacteria from many of the innate immune defenses, such as phagocytosis by neutrophils (Justice et al., <xref ref-type="bibr" rid="B19">2004</xref>), but also from antibiotics that often are ineffective in eliminating intracellular bacteria (Blango and Mulvey, <xref ref-type="bibr" rid="B3">2010</xref>). The subsequent resurgence of these intracellular reservoirs can be the cause of recurrent or chronic UTI (Rosen et al., <xref ref-type="bibr" rid="B31">2007</xref>). UPEC exhibit morphological plasticity within the IBCs (Justice et al., <xref ref-type="bibr" rid="B19">2004</xref>, <xref ref-type="bibr" rid="B20">2006</xref>; Horvath et al., <xref ref-type="bibr" rid="B18">2011</xref>). In the initial phase, bacteria transform from a rod shape to coccoid morphology that may follow by an additional transition into a filamentous form (Justice et al., <xref ref-type="bibr" rid="B19">2004</xref>; Horvath et al., <xref ref-type="bibr" rid="B18">2011</xref>). As bacteria emerge from the IBC they may do so in a filamentous form (Justice et al., <xref ref-type="bibr" rid="B19">2004</xref>). Filamentous <italic>E. coli</italic> have been observed in urine from women with UTI and the filamentation <italic>per se</italic> may serve as a strategy to resist host immune responses, such as phagocytosis (Horvath et al., <xref ref-type="bibr" rid="B18">2011</xref>), but may also be seen as a more general stress response. Filamentation can be induced by components of an activated host defense system (Justice et al., <xref ref-type="bibr" rid="B20">2006</xref>), shear stress (Khandige et al., <xref ref-type="bibr" rid="B21">2016</xref>) and also in response to treatment with different beta-lactam antibiotics, in particular, aminothiazolyl cephalosporins like ceftibuten. Beta-lactam antibiotics induce <italic>E. coli</italic> filamentation by inhibiting penicillin-binding protein-3 (PBP-3) that catalyzes septa formation (Gould and MacKenzie, <xref ref-type="bibr" rid="B17">1997</xref>). SulA, a member of the bacterial SOS DNA damage repair system, has also been shown to induce bacterial filamentation. It was recently shown that cell division gene <italic>damX</italic> is also a mediator of reversible filamentation of UPEC (Khandige et al., <xref ref-type="bibr" rid="B21">2016</xref>). We have previously shown that filamentation of extended spectrum &#x003B2;-lactamase (ESBL)-producing UPEC isolates can alter the ability of UPEC to evoke pro-inflammatory responses in renal epithelial cells and neutrophils (Demirel et al., <xref ref-type="bibr" rid="B12">2015</xref>). Therefore, knowledge of the virulence factors expressed by different morphological forms of UPEC may be used to devise novel therapeutic strategies to obstruct these virulence factors in order to inhibit pathogenesis.</p>
<p>A major concern and emerging health problem is the increasing incidence of antibiotic resistance among uropathogenic strains (Coque et al., <xref ref-type="bibr" rid="B11">2008</xref>; Brolund, <xref ref-type="bibr" rid="B7">2014</xref>). A majority of the ESBL-producing bacteria are isolated from urine samples (Pitout and Laupland, <xref ref-type="bibr" rid="B28">2008</xref>; Khanfar et al., <xref ref-type="bibr" rid="B22">2009</xref>). In addition, mortality has been shown to increase in ESBL-induced infections proportionally with the duration of the delay in effective treatment, making the choice of correct antibiotics critical for patients (Tumbarello et al., <xref ref-type="bibr" rid="B36">2007</xref>).</p>
<p>The virulence capacity of ESBL-producing UPECs during their morphological shifts remains to be properly studied. The aim of the present study was to investigate changes in global gene expression patterns and in virulence factor-associated genes in ESBL-producing UPEC during the morphologic transitions induced by ineffective antibiotics in the presence of human primary bladder epithelial cells.</p>
</sec>
<sec id="s2">
<title>Material and methods</title>
<sec>
<title>Cell and bacterial culture</title>
<p>Primary human bladder epithelium progenitor cells (HBEP, CELLnTEC Advanced Cell Systems AG, Bern, Switzerland) were cultured in wells with CnT-58 cell culture medium (CELLnTEC) supplemented with 100 U/mL penicillin and 100 &#x003BC;L/mg streptomycin (both from Invitrogen Ltd, Paisley, UK) in a humidified atmosphere with 5% CO<sub>2</sub> at 37&#x000B0;C. At confluency the culture was differentiated during 4 days using CnT-21 differentiation medium (CELLnTEC) supplemented with 1 mM CaCl<sub>2</sub>. The ESBL-producing UPEC was originally isolated from a patient at &#x000D6;rebro University hospital, Sweden. The isolate, designated ESBL019 (previously named ESBL7, Demirel et al., <xref ref-type="bibr" rid="B12">2015</xref>), has previously been characterized and determined to be multidrug resistant (CTX-M-15) and resistant to ceftibuten (MIC 7,680 ng/ml) and belongs to the ST131 clone (Onnberg et al., <xref ref-type="bibr" rid="B26">2011</xref>). ESBL019 was grown in Luria broth (Difco Laboratories, Detroit, MI, USA) overnight on shake at 200 rpm 37&#x000B0;C. The bacteria were resuspended in sterile phosphate buffered saline prior to inoculation of CnT-21 cell culture medium (CCM) with or without ceftibuten (480 ng/mL). The antibiotic concentration used is a reference minimal inhibitory concentration (MIC) of ceftibuten that was determined on two antibiotic susceptible UPEC isolates as previously defined (Demirel et al., <xref ref-type="bibr" rid="B12">2015</xref>).</p>
</sec>
<sec>
<title>Morphologic transitions and evaluation</title>
<p>Four morphologic states of ESBL019 were used during the experiments (Figure <xref ref-type="fig" rid="F1">1</xref>). A first ESBL019 morphological state was prepared by resuspension of ESBL019 in CCM without ceftibuten supplementation prior to its inoculation of HBEP cells without ceftibuten (designated; ESBL019 Coliform). A second ESBL019 morphological state was prepared by resuspension in CCM and then used to inoculate HBEP cells with ceftibuten supplementation (480 ng/mL) (designated; ESBL019 Transition). This transition from coliform into filamented occurs in the presence of HBEP cells. A third ESBL019 morphological state was prepared by resuspension and pre-incubation for 3 h in CCM with ceftibuten in a tube, in order to induce complete filamentation of all bacteria. Filamentation was confirmed by microscopy. The third pre-filamented ESBL019 fraction was used to inoculate HBEP cells in the presence of ceftibuten to keep the bacteria filamented (designated; ESBL019 Filamented). The CCM of the pre-filamented ESBL019 fraction was replaced with CCM without ceftibuten and the filamented ESBL019 were allowed to revert completely back to its coliform during 1 h in a tube prior to the inoculation of HBEP cells without ceftibuten (designated; ESBL019 Reverted) (Figure <xref ref-type="fig" rid="F1">1</xref>). The bacterial morphologies were evaluated with an Olympus CKX41 inverted light microscope (Olympus, Segrate, Italy). Prior to inoculation the bacterial concentrations of all fractions were adjusted in order to inoculate HBEP cells with a multiplicity of infection (MOI) of 10. All inoculated cells were incubated for 4 h in 5% CO<sub>2</sub> at 37&#x000B0;C after which supernatants were collected and centrifuged 5 min at 5,000 &#x000D7; g to collect the extracellular bacteria. The viability of the HBEP cells was &#x0003E;90% after the infection as determined by the neutral red assay. The HBEP cells were then lysed with sterile MQ water for 3 min and the intracellular bacteria were collected and centrifuged for 5 min at 5,000 &#x000D7; g followed by a washing step with PBS.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Summary of the experimental design, morphological transition and visual evaluation by light microscope of the different forms of ESBL019. Scale bar: 100 &#x003BC;m.</p></caption>
<graphic xlink:href="fmicb-08-01058-g0001.tif"/>
</fig>
</sec>
<sec>
<title>RNA preparation and microarray</title>
<p>Total RNA was isolated from the combined intra-and extracellular bacteria with the RNeasy Mini Kit (Qiagen Technologies, Hilden, Germany) according to manufacturer instructions. Contaminating DNA was removed by DNase digestion (TURBO DNase, Life technologies, MA, USA) according to manufacturer instructions. RNA concentration and purity were determined using a Nano-Drop ND-1000 Spectrophotometer (Nano-Drop Technology Inc., Wilmington, DE, USA). All samples had OD260/280 and OD260/230 ratios above 1.9. RNA quality was further evaluated using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) according to manufacturer instructions. All samples had RNA integrity number (RIN) values above 9. High-quality total RNA from four biological replicates was used to prepare labeled cRNA with Low Input Quick Amp WT Labeling Kits (Agilent) according to manufacturer instructions. Labeled cRNA samples were hybridized in a G2545A hybridization oven (Agilent) onto Agilent SurePrint G3 <italic>E. coli</italic> Gene Expression 8x15k (Agilent Technologies) glass arrays according to manufacturer instructions and subsequently scanned with a G2565 CA array laser scanner (Agilent Technologies). Image analysis and data extraction was performed with Feature Extraction Software (version 10.7.3.1, Agilent Technologies). The virulence factor list for <italic>E. coli</italic> was generated through the use of virulence association in the PATRIC database (<ext-link ext-link-type="uri" xlink:href="http://www.patricbrc.org">www.patricbrc.org</ext-link>) with the addition of MESH virulence search term associated genes and literature mining. Gene expression data is available in the GEO database with the accession number <ext-link ext-link-type="NCBI:geo" xlink:href="GSE99661">GSE99661</ext-link>.</p>
</sec>
<sec>
<title>Quantitative real-time PCR (qPCR)</title>
<p>cDNA synthesis (200 ng of total RNA) was performed by using High Capacity cDNA Reverse Transcription Kit for single-stranded cDNA synthesis (Applied Biosystems, CA, USA) according to manufacturer&#x02018;s protocol. Maxima SYBR Green qPCR Master Mix (ThermoFisher Scientific, MA, USA) was used for the qPCR according to manufacturer&#x00027;s instructions. Two hundred and fifty nanometer of primer and 10 ng template cDNA was added to each reaction. Primers were ordered from Eurofins MWG Synthesis GmbH (Ebersberg, Munich, Germany) (Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>). The amplification was performed in a CFX96 Touch&#x02122; Real-Time PCR Detection System (Biorad, CA, USA) using the following protocol: initial denaturation at 95&#x000B0;C for 10 min, 40 cycles of denaturation at 95&#x000B0;C for 15 s followed by annealing at 60&#x000B0;C for 30 s and extension at 72&#x000B0;C for 30 s. The PCR was followed by a dissociation curve analysis between 60 and 95&#x000B0;C. The Ct values were analyzed by the comparative Ct (&#x00394;&#x00394;Ct) method and normalized to the endogenous control gapA (encoding glyceraldehyde 3-phosphate dehydrogenase A). Fold difference was calculated as 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup>.</p>
</sec>
<sec>
<title>Transmission electron microscopy</title>
<p>ESBL019 was prepared for electron microscopy with or without ceftibuten as previously mentioned, but without the presence of HBEP cells. ESBL019 was washed in PBS before fixation with 5% glutaraldehyde in 0.1 M phosphate buffer. The bacteria were absorbed on carbon-coated copper grids and contrasted with 1% uranyl acetate solution. A JEOL JEM 1230 transmission electron microscope at 80-kV accelerating voltage was used for examination and images were recorded with a Gatan Multiscan 791 CCD camera.</p>
</sec>
<sec>
<title>Agglutination assays</title>
<p>ESBL019 in its four different morphological states were collected after HBEP inoculation to measure Type-1-and P-fimbriae phenotype expression. The expression of Type-1 fimbriae was evaluated using 5% yeast diluted in PBS and the expression of P-fimbriae was evaluated using 2% of P-positive human erythrocytes diluted in PBS. All the bacteria from the well were mixed 1:1 (v/v) with yeast or erythrocytes on a glass slide and agglutination was evaluated with an Olympus CKX41 inverted light microscope.</p>
</sec>
<sec>
<title>Measurement of TNF-&#x003B1; release from primary bladder epithelial cells</title>
<p>An enzyme-linked immunosorbent assay (ELISA) was performed to measure the TNF-&#x003B1; release from HBEP cells in response to the different morphological states of ESBL019. TNF-&#x003B1; was measured using the human TNF-&#x003B1; kit (ELISA MAX&#x02122; Standard, BioLegend, San Diego, CA, USA) according to the manufacturer&#x00027;s protocol and measured on a spectrophotometer (Multiskan Ascent, Thermo Labsystems, Helsingfors, Finland).</p>
</sec>
<sec>
<title>Statistical analysis and microarray data processing</title>
<p>All microarray data analysis was performed using Gene Spring GX version 13.0 (Agilent Technologies) after per chip and gene 75th percentile shift normalization of samples. Different expression between groups was analyzed with one-way analysis of variance (ANOVA) parametric test. Significantly expressed entities (<italic>p</italic> &#x0003C; 0.05) was obtained by Tukey HSD <italic>post hoc</italic> test followed by Bonferroni multiple testing correction and a fold change set at &#x02265;2. Significance for GO term enrichment and single experiment pathway analysis were set at a <italic>p</italic>-value &#x0003C; 0.05 and <italic>p</italic>-value &#x0003C; 0.1 respectively. The virulence factor list for <italic>E. coli</italic> was generated through the use of virulence association in the PATRIC database (<ext-link ext-link-type="uri" xlink:href="http://www.patricbrc.org">www.patricbrc.org</ext-link>) with the addition of MESH virulence search term associated genes and literature mining. In total the list was composed of 305 genes classified as associated with or designated to virulence. The differences between groups in the ELISA assay were evaluated with one-way ANOVA followed by Bonferroni test. The differences compared to ESBL019 Coliform in the qPCR were evaluated with Student&#x00027;s unpaired <italic>t</italic>-test. Differences were considered statistically significant when <italic>p</italic> &#x0003C; 0.05. Data are presented as mean &#x000B1; standard error of the mean (SEM), <italic>n</italic> &#x0003D; number of independent experiments.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Morphological plasticity of <italic>E. coli</italic> in response to ceftibuten exposure</title>
<p>ESBL019 is a strain resistant to ceftibuten. It changed morphology from its normal coliform into a filamentous form (&#x0003E;100 &#x003BC;m) after exposure to ceftibuten in the presence of human primary bladder epithelial cells (HBEP). This transition in the presence of HBEP is defined as ESBL019 Transition. The filamentation process started as early as 1 h after the addition of ceftibuten and the bacteria reached full filamentation approximately 3 h after exposure to ceftibuten. After removing ceftibuten from the growth medium, the filamentous ESBL019 reverted completely back to its coliform within 1 h (Figure <xref ref-type="fig" rid="F1">1</xref>). Transmission electron microscopy showed a normal Coliformed bacteria (Figure <xref ref-type="fig" rid="F2">2A</xref>) and that the septa between the bacteria was not fully formed in the filamented phase (Figure <xref ref-type="fig" rid="F2">2B</xref>). The reversion from the filamentous form back to the coliform was associated with formation of the bacterial septa (Figures <xref ref-type="fig" rid="F2">2C,D</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Visual evaluation of the different forms of ESBL019 by transmission electron microscope. ESBL019 Coliform <bold>(A)</bold> was grown for 3 h without ceftibuten, ESBL019 Filamented <bold>(B)</bold> was grown for 3 h in the presence of ceftibuten and ESBL019 Reverted <bold>(C,D)</bold> was grown in the presence of ceftibuten for the first 3 h and then without for 1 h to allowed the bacteria to revert completely back to its coliform. Septa formation during reversion can also be observed <bold>(C)</bold>. Scale bar: 0.5 &#x003BC;m <bold>(A,C,D)</bold> 2 &#x003BC;m <bold>(B)</bold>.</p></caption>
<graphic xlink:href="fmicb-08-01058-g0002.tif"/>
</fig>
</sec>
<sec>
<title>Gene expression alterations in the different morphological phases</title>
<p>Microarray analysis was performed on total RNA isolated from (intra and extracellular) bacteria prior to and following their morphological transition from coliform to filamentous form and then reverted to their original coliform. In total 6438 entities were differentially expressed (<italic>p</italic> &#x0003C; 0.05) with at least a &#x02265;2 fold change compared to the ESBL019 Coliform. All three morphological states, ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted, induced changes in gene expressions with 683, 3,720, and 1,951 up-regulated and 283, 1,026, and 827 down-regulated gene expressions, respectively (Figure <xref ref-type="fig" rid="F3">3</xref>). A total of 739 altered gene entities are shared between ESBL019 Transition and ESBL019 Filamented with 585 up-regulated and 157 down-regulated entities, and 1,239 gene entities were shared between ESBL019 Filamented and ESBL019 Reverted with 914 up-regulated and 325 down-regulated entities. In addition, 381 shared gene entities were differentially expressed in all three groups (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Venn diagram of differentially expresses entities. Red represents ESBL019 Transition compared to ESBL019 Coliform, blue represents E7 Filamented compared to ESBL019 Coliform and green represents ESBL019 Reverted compared to E7 Coliform. Overlapping regions represents shared entities. Up- and down-regulated entities are designated U and D respectively. <italic>n</italic> &#x0003D; 4 per group.</p></caption>
<graphic xlink:href="fmicb-08-01058-g0003.tif"/>
</fig>
</sec>
<sec>
<title>Gene ontology and pathway analysis</title>
<p>Gene ontology (GO) analysis was performed on significantly altered gene entities compared to ESBL019 Coliform expression. In total, 14 (ESBL019 Transition), 9 (ESBL019 Filamented) and 4 (ESBL019 Reverted) gene ontologies were uniquely enriched (Table <xref ref-type="supplementary-material" rid="SM2">S2</xref>). Single experiment pathway analysis (SEA) (<italic>p</italic> &#x0003C; 0.05) was performed in order to determine significantly affected cellular pathways. In total, 33 pathways were altered, of which 30 pathways were related to metabolism and the rest to enterobactin biosynthesis and polymyxin resistance (Table <xref ref-type="supplementary-material" rid="SM3">S3</xref>).</p>
</sec>
<sec>
<title>Virulence factors in the different morphological states</title>
<p>Next, a more detailed analysis of the alterations in expression patterns of virulence associated genes of ESBL019 was conducted. The compiled list of virulence factor associated genes, 305 entities in total, was used to filter out significantly altered entities associated with virulence in the different groups. In total, 199 altered gene entities were identified with association to virulence. These 199 altered gene entities were grouped into 10 different functional groups; Adhesion, Growth, LPS synthesis, Metabolism, Motility, Protection, Siderophore, Toxins, Secretion and Transcription regulation. Of the 199 genes, 19 genes had significantly altered expressions in all three morphological states compared to the original ESBL019 Coliform (Table <xref ref-type="table" rid="T1">1A</xref>). The ESBL019 Transition state showed altered expression of 33 virulence associated genes (Tables <xref ref-type="table" rid="T1">1A</xref>,<xref ref-type="table" rid="T2">B</xref>). The ESBL019 Filamented state showed the single largest alteration in virulence associated gene expression. A total of 149 altered expression in genes was observed in the ESBL019 Filamented state (Tables <xref ref-type="table" rid="T1">1A</xref>,<xref ref-type="table" rid="T2">B</xref>). The ESBL019 Reverted state showed altered expression of 92 virulence associated genes (Tables <xref ref-type="table" rid="T1">1A</xref>,<xref ref-type="table" rid="T2">B</xref>).</p>
<table-wrap position="float" id="T1">
<label>Table 1A</label>
<caption><p>Shared virulence factors associated genes present among significantly altered entities in ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted compared to ESBL019 Coliform.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Function</bold></th>
<th valign="top" align="left"><bold>Gene</bold></th>
<th valign="top" align="center" style="border-bottom: thin solid #000000;"><bold>ESBL019 Coliform</bold></th>
<th valign="top" align="center" colspan="3" style="border-bottom: thin solid #000000;"><bold>Fold change vs. ESBL019 coliform</bold></th>
<th valign="top" align="left"><bold>Description</bold></th>
</tr>
<tr>
<th/>
<th/>
<th valign="top" align="center"><bold>Normalized entity fluorescence intensity signals</bold></th>
<th valign="top" align="center"><bold>ESBL019 transition</bold></th>
<th valign="top" align="center"><bold>ESBL019 filamentous</bold></th>
<th valign="top" align="center"><bold>ESBL019 reverted</bold></th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Adhesin</td>
<td valign="top" align="left">papG</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">2.4</td>
<td valign="top" align="center">3.0</td>
<td valign="top" align="center">2.7</td>
<td valign="top" align="left">PapG protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papF</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">2.8</td>
<td valign="top" align="center">4.2</td>
<td valign="top" align="center">2.2</td>
<td valign="top" align="left">PapF protein</td>
</tr>
<tr>
<td valign="top" align="left">Growth</td>
<td valign="top" align="left">carB</td>
<td valign="top" align="center">7,750</td>
<td valign="top" align="center">&#x02212;2.5</td>
<td valign="top" align="center">&#x02212;6.0</td>
<td valign="top" align="center">&#x02212;2.7</td>
<td valign="top" align="left">Carbamoyl-phosphate synthase large subunit</td>
</tr>
<tr>
<td valign="top" align="left">LPS synthesis</td>
<td valign="top" align="left">waaV</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">3.0</td>
<td valign="top" align="center">4.3</td>
<td valign="top" align="center">2.3</td>
<td valign="top" align="left">Putative beta1.3-glucosyltransferase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">rfbC</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">2.9</td>
<td valign="top" align="center">6.5</td>
<td valign="top" align="center">2.7</td>
<td valign="top" align="left">dTDP-6-deoxy-D-glucose-3.5 epimerase</td>
</tr>
<tr>
<td valign="top" align="left">Metabolism</td>
<td valign="top" align="left">mglB</td>
<td valign="top" align="center">2,552</td>
<td valign="top" align="center">&#x02212;3.7</td>
<td valign="top" align="center">&#x02212;10.0</td>
<td valign="top" align="center">3.5</td>
<td valign="top" align="left">D-galactose-binding periplasmic protein precursor</td>
</tr>
<tr>
<td valign="top" align="left">Motility</td>
<td valign="top" align="left">fliC</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">2.4</td>
<td valign="top" align="center">3.8</td>
<td valign="top" align="center">2.2</td>
<td valign="top" align="left">Flagellar biosynthesis flagellin. filament structural protein</td>
</tr>
<tr>
<td valign="top" align="left">Protection</td>
<td valign="top" align="left">tcpC</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">&#x02212;4.2</td>
<td valign="top" align="center">&#x02212;4.1</td>
<td valign="top" align="center">&#x02212;2.1</td>
<td valign="top" align="left">TCP pilus biosynthesis protein tcpC</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ompT</td>
<td valign="top" align="center">5,577</td>
<td valign="top" align="center">2.5</td>
<td valign="top" align="center">&#x02212;2.7</td>
<td valign="top" align="center">&#x02212;5.2</td>
<td valign="top" align="left">Protease VII precursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">wcaE</td>
<td valign="top" align="center">13</td>
<td valign="top" align="center">3.6</td>
<td valign="top" align="center">31.7</td>
<td valign="top" align="center">3.2</td>
<td valign="top" align="left">Putative colanic acid biosynthesis glycosyl transferase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ibpA</td>
<td valign="top" align="center">155</td>
<td valign="top" align="center">7.1</td>
<td valign="top" align="center">37.4</td>
<td valign="top" align="center">4.3</td>
<td valign="top" align="left">Heat shock protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ibpB</td>
<td valign="top" align="center">124</td>
<td valign="top" align="center">6.0</td>
<td valign="top" align="center">56.6</td>
<td valign="top" align="center">12.0</td>
<td valign="top" align="left">Heat shock protein</td>
</tr>
<tr>
<td valign="top" align="left">Siderophore</td>
<td valign="top" align="left">sitB</td>
<td valign="top" align="center">1,841</td>
<td valign="top" align="center">&#x02212;4.5</td>
<td valign="top" align="center">&#x02212;10.9</td>
<td valign="top" align="center">&#x02212;2.8</td>
<td valign="top" align="left">SitB protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">chuT</td>
<td valign="top" align="center">1,255</td>
<td valign="top" align="center">&#x02212;7.0</td>
<td valign="top" align="center">&#x02212;9.1</td>
<td valign="top" align="center">&#x02212;2.3</td>
<td valign="top" align="left">Putative Periplasmic binding protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fepE</td>
<td valign="top" align="center">5,165</td>
<td valign="top" align="center">&#x02212;2.4</td>
<td valign="top" align="center">&#x02212;5.4</td>
<td valign="top" align="center">&#x02212;2.9</td>
<td valign="top" align="left">Ferric enterobactin transport protein fepE</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fepA</td>
<td valign="top" align="center">2,007</td>
<td valign="top" align="center">&#x02212;3.0</td>
<td valign="top" align="center">&#x02212;3.9</td>
<td valign="top" align="center">&#x02212;2.6</td>
<td valign="top" align="left">Ferrienterobactin receptor precursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">iroN</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">2.6</td>
<td valign="top" align="center">3.5</td>
<td valign="top" align="center">2.9</td>
<td valign="top" align="left">Siderophore receptor IroN</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">entF</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">2.4</td>
<td valign="top" align="center">3.7</td>
<td valign="top" align="center">2.0</td>
<td valign="top" align="left">ATP-dependent serine activating enzyme</td>
</tr>
<tr>
<td valign="top" align="left">Toxins</td>
<td valign="top" align="left">hlyC</td>
<td valign="top" align="center">7</td>
<td valign="top" align="center">2.8</td>
<td valign="top" align="center">3.7</td>
<td valign="top" align="center">2.1</td>
<td valign="top" align="left">Hemolysin C</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap position="float" id="T2">
<label>Table 1B</label>
<caption><p>Virulence factors associated genes present among significantly altered entities in ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted compared to ESBL019 Coliform.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Function</bold></th>
<th valign="top" align="left"><bold>Gene</bold></th>
<th valign="top" align="center" style="border-bottom: thin solid #000000;"><bold>ESBL019 coliform</bold></th>
<th valign="top" align="center" colspan="3" style="border-bottom: thin solid #000000;"><bold>Fold change vs. ESBL019 Coliform</bold></th>
<th valign="top" align="left"><bold>Description</bold></th>
</tr>
<tr>
<th/>
<th/>
<th valign="top" align="center"><bold>Normalized entity fluorescence intensity signals</bold></th>
<th valign="top" align="center"><bold>ESBL019 transition</bold></th>
<th valign="top" align="center"><bold>ESBL019 filamentous</bold></th>
<th valign="top" align="center"><bold>ESBL019 reverted</bold></th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Protection</td>
<td valign="top" align="left">degP</td>
<td valign="top" align="center">6,718</td>
<td valign="top" align="center">2.1</td>
<td/>
<td/>
<td valign="top" align="left">Periplasmic serine protease Do; heat shock protein HtrA</td>
</tr>
<tr>
<td valign="top" align="left">Siderophore</td>
<td valign="top" align="left">shiF</td>
<td valign="top" align="center">344</td>
<td valign="top" align="center">&#x02212;3.0</td>
<td/>
<td/>
<td valign="top" align="left">ShiF protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fepC</td>
<td valign="top" align="center">119</td>
<td valign="top" align="center">&#x02212;2.1</td>
<td/>
<td/>
<td valign="top" align="left">ATP-binding component of ferric enterobactin transport</td>
</tr>
<tr>
<td valign="top" align="left">Toxins</td>
<td valign="top" align="left">hlyA</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">&#x02212;2.6</td>
<td/>
<td/>
<td valign="top" align="left">Hemolysin A</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Growth</td>
<td valign="top" align="left">carA</td>
<td valign="top" align="center">3,789</td>
<td valign="top" align="center">&#x02212;2.2</td>
<td valign="top" align="center">&#x02212;2.3</td>
<td/>
<td valign="top" align="left">Carbamoyl-phosphate synthetase. glutamine</td>
</tr>
<tr>
<td valign="top" align="left">Metabolism</td>
<td valign="top" align="left">mglA</td>
<td valign="top" align="center">801</td>
<td valign="top" align="center">&#x02212;4.5</td>
<td valign="top" align="center">&#x02212;16.2</td>
<td/>
<td valign="top" align="left">ATP-bind. comp. of methyl-galactoside transp. and galactose taxis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">dctA</td>
<td valign="top" align="center">3,224</td>
<td valign="top" align="center">&#x02212;5.0</td>
<td valign="top" align="center">&#x02212;8.0</td>
<td/>
<td valign="top" align="left">Uptake of C4-dicarboxylic acids</td>
</tr>
<tr>
<td valign="top" align="left">Protection</td>
<td valign="top" align="left">ivy</td>
<td valign="top" align="center">1,292</td>
<td valign="top" align="center">3.3</td>
<td valign="top" align="center">4.4</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td valign="top" align="left">Siderophore</td>
<td valign="top" align="left">entE</td>
<td valign="top" align="center">763</td>
<td valign="top" align="center">&#x02212;2.3</td>
<td valign="top" align="center">&#x02212;5.7</td>
<td/>
<td valign="top" align="left">2.3-dihydroxybenzoate-AMP ligase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">entC</td>
<td valign="top" align="center">708</td>
<td valign="top" align="center">&#x02212;2.9</td>
<td valign="top" align="center">&#x02212;4.3</td>
<td/>
<td valign="top" align="left">isochorismate hydroxymutase 2. enterochelin biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">iucA</td>
<td valign="top" align="center">641</td>
<td valign="top" align="center">&#x02212;2.2</td>
<td valign="top" align="center">&#x02212;2.9</td>
<td/>
<td valign="top" align="left">IucA protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fepB</td>
<td valign="top" align="center">269</td>
<td valign="top" align="center">&#x02212;2.2</td>
<td valign="top" align="center">&#x02212;2.6</td>
<td/>
<td valign="top" align="left">Ferric enterobactin</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">iroB</td>
<td valign="top" align="center">10</td>
<td valign="top" align="center">2.0</td>
<td valign="top" align="center">2.7</td>
<td/>
<td valign="top" align="left">Putative glucosyltransferase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">chuA</td>
<td valign="top" align="center">595</td>
<td valign="top" align="center">&#x02212;2.0</td>
<td valign="top" align="center">&#x02212;2.5</td>
<td/>
<td valign="top" align="left">Outer membrane heme/hemoglobin receptor</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Adhesin</td>
<td valign="top" align="left">papX</td>
<td valign="top" align="center">3,768</td>
<td/>
<td valign="top" align="center">&#x02212;5.5</td>
<td/>
<td valign="top" align="left">PapX protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">focX</td>
<td valign="top" align="center">6,009</td>
<td/>
<td valign="top" align="center">&#x02212;5.4</td>
<td/>
<td valign="top" align="left">Putative Regulatory protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">csgE</td>
<td valign="top" align="center">234</td>
<td/>
<td valign="top" align="center">&#x02212;2.5</td>
<td/>
<td valign="top" align="left">Curli production assembly/transport component. 2nd curli operon</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flu</td>
<td valign="top" align="center">796</td>
<td/>
<td valign="top" align="center">&#x02212;2.4</td>
<td/>
<td valign="top" align="left">Outer membrane fluffing protein. similar to adhesin</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ompA</td>
<td valign="top" align="center">145,147</td>
<td/>
<td valign="top" align="center">&#x02212;2.2</td>
<td/>
<td valign="top" align="left">Outer membrane protein 3a</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">sfaB</td>
<td valign="top" align="center">40</td>
<td/>
<td valign="top" align="center">2.4</td>
<td/>
<td valign="top" align="left">Putative F1C and S fimbrial switch Regulatory</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papI</td>
<td valign="top" align="center">20</td>
<td/>
<td valign="top" align="center">2.6</td>
<td/>
<td valign="top" align="left">PapI protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">phoU</td>
<td valign="top" align="center">1,346</td>
<td/>
<td valign="top" align="center">2.7</td>
<td/>
<td valign="top" align="left">neg. reg. for pho regulon and putative enzyme in phosphate metab.</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">focG</td>
<td valign="top" align="center">18</td>
<td/>
<td valign="top" align="center">2.7</td>
<td/>
<td valign="top" align="left">F1C minor fimbrial subunit protein G presursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">focD</td>
<td valign="top" align="center">11</td>
<td/>
<td valign="top" align="center">2.9</td>
<td/>
<td valign="top" align="left">F1C fimbrial usher</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papH</td>
<td valign="top" align="center">12</td>
<td/>
<td valign="top" align="center">3.1</td>
<td/>
<td valign="top" align="left">PapH protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">focC</td>
<td valign="top" align="center">14</td>
<td/>
<td valign="top" align="center">3.1</td>
<td/>
<td valign="top" align="left">F1C periplasmic chaperone</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">focH</td>
<td valign="top" align="center">23</td>
<td/>
<td valign="top" align="center">3.1</td>
<td/>
<td valign="top" align="left">F1C Putative fimbrial adhesin precursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">csgA</td>
<td valign="top" align="center">5</td>
<td/>
<td valign="top" align="center">3.3</td>
<td/>
<td valign="top" align="left">Curlin major subunit. coiled surface structures; cryptic</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">focF</td>
<td valign="top" align="center">14</td>
<td/>
<td valign="top" align="center">3.4</td>
<td/>
<td valign="top" align="left">F1C minor fimbrial subunit F precursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papA</td>
<td valign="top" align="center">21</td>
<td/>
<td valign="top" align="center">3.6</td>
<td/>
<td valign="top" align="left">PapA protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papK</td>
<td valign="top" align="center">10</td>
<td/>
<td valign="top" align="center">3.7</td>
<td/>
<td valign="top" align="left">PapK protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papD</td>
<td valign="top" align="center">1,267</td>
<td/>
<td valign="top" align="center">3.9</td>
<td/>
<td valign="top" align="left">PapD protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papC</td>
<td valign="top" align="center">9</td>
<td/>
<td valign="top" align="center">3.9</td>
<td/>
<td valign="top" align="left">PapC protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">papE</td>
<td valign="top" align="center">13</td>
<td/>
<td valign="top" align="center">4.0</td>
<td/>
<td valign="top" align="left">PapE protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimE</td>
<td valign="top" align="center">351</td>
<td/>
<td valign="top" align="center">5.5</td>
<td/>
<td valign="top" align="left">Recombinase involved in phase variation; regulator for fimA</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimB</td>
<td valign="top" align="center">40</td>
<td/>
<td valign="top" align="center">6.8</td>
<td/>
<td valign="top" align="left">Recombinase involved in phase variation; regulator for fimA</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">LPS synthesis</td>
<td valign="top" align="left">waaI</td>
<td valign="top" align="center">14</td>
<td/>
<td valign="top" align="center">2.2</td>
<td/>
<td valign="top" align="left">Putative LPS biosynthesis enzyme</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">waaJ</td>
<td valign="top" align="center">3</td>
<td/>
<td valign="top" align="center">2.2</td>
<td/>
<td valign="top" align="left">Putative LPS biosynthesis enzyme</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">waaL</td>
<td valign="top" align="center">39</td>
<td/>
<td valign="top" align="center">2.5</td>
<td/>
<td valign="top" align="left">Lipid A-core. surface polymer ligase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">waaA</td>
<td valign="top" align="center">105</td>
<td/>
<td valign="top" align="center">2.7</td>
<td/>
<td valign="top" align="left">3-deoxy-D-manno-octulosonic-acid transferase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">yibD</td>
<td valign="top" align="center">93</td>
<td/>
<td valign="top" align="center">3.2</td>
<td/>
<td valign="top" align="left">Putative regulator</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">rfbA</td>
<td valign="top" align="center">23</td>
<td/>
<td valign="top" align="center">3.2</td>
<td/>
<td valign="top" align="left">Glucose-1-phosphate thymidylyltransferase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">waaY</td>
<td valign="top" align="center">11</td>
<td/>
<td valign="top" align="center">3.8</td>
<td/>
<td valign="top" align="left">Putative LPS biosynthesis protein</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Metabolism</td>
<td valign="top" align="left">dppA</td>
<td valign="top" align="center">8,306</td>
<td/>
<td valign="top" align="center">&#x02212;8.6</td>
<td/>
<td valign="top" align="left">Dipeptide transport protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">narH</td>
<td valign="top" align="center">262</td>
<td/>
<td valign="top" align="center">&#x02212;4.1</td>
<td/>
<td valign="top" align="left">Nitrate reductase 1. beta subunit</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">narG</td>
<td valign="top" align="center">214</td>
<td/>
<td valign="top" align="center">&#x02212;3.9</td>
<td/>
<td valign="top" align="left">Nitrate reductase 1. alpha subunit</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fruR</td>
<td valign="top" align="center">3,876</td>
<td/>
<td valign="top" align="center">&#x02212;3.3</td>
<td/>
<td valign="top" align="left">Transcriptional repressor of fru operon and others</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">deoC</td>
<td valign="top" align="center">1,595</td>
<td/>
<td valign="top" align="center">&#x02212;2.6</td>
<td/>
<td valign="top" align="left">2-deoxyribose-5-phosphate aldolase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">malX</td>
<td valign="top" align="center">201</td>
<td/>
<td valign="top" align="center">&#x02212;2.3</td>
<td/>
<td valign="top" align="left">PTS system. maltose and glucose-specific II ABC</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">lysR</td>
<td valign="top" align="center">81</td>
<td/>
<td valign="top" align="center">2.1</td>
<td/>
<td valign="top" align="left">Positive regulator for lys</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ycjV</td>
<td valign="top" align="center">10</td>
<td/>
<td valign="top" align="center">2.5</td>
<td/>
<td valign="top" align="left">Putative ATP-binding component of a transport system</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gatC</td>
<td valign="top" align="center">88</td>
<td/>
<td valign="top" align="center">2.6</td>
<td/>
<td valign="top" align="left">PTS system galactitol-specific enzyme IIC</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">btuB</td>
<td valign="top" align="center">147</td>
<td/>
<td valign="top" align="center">2.8</td>
<td/>
<td valign="top" align="left">Outer memb. Rec. for transp. of vit B12. E colicins and bact.phage</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">wbdP</td>
<td valign="top" align="center">3</td>
<td/>
<td valign="top" align="center">3.0</td>
<td/>
<td valign="top" align="left">Glycosyl transferase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ycfQ</td>
<td valign="top" align="center">354</td>
<td/>
<td valign="top" align="center">3.2</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">yedL</td>
<td valign="top" align="center">5</td>
<td/>
<td valign="top" align="center">3.6</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ycjM</td>
<td valign="top" align="center">69</td>
<td/>
<td valign="top" align="center">8.6</td>
<td/>
<td valign="top" align="left">Putative sucrose phosphorylase</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Motility</td>
<td valign="top" align="left">flhD</td>
<td valign="top" align="center">638</td>
<td/>
<td valign="top" align="center">&#x02212;5.6</td>
<td/>
<td valign="top" align="left">reg. of flag. biosynth. acting on class 2 operons; transcrip. Init. factor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flhC</td>
<td valign="top" align="center">365</td>
<td/>
<td valign="top" align="center">&#x02212;3.5</td>
<td/>
<td valign="top" align="left">reg. of flag. Biosynth. acting on class 2 operons; transcrip. Init. factor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliY</td>
<td valign="top" align="center">3,253</td>
<td/>
<td valign="top" align="center">&#x02212;2.5</td>
<td/>
<td valign="top" align="left">Putative periplasmic binding transport protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flgM</td>
<td valign="top" align="center">281</td>
<td/>
<td valign="top" align="center">&#x02212;2.1</td>
<td/>
<td valign="top" align="left">Anti-FliA</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliG</td>
<td valign="top" align="center">22</td>
<td/>
<td valign="top" align="center">2.1</td>
<td/>
<td valign="top" align="left">flag. biosynth. component of motor switching and energizing</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliZ</td>
<td valign="top" align="center">156</td>
<td/>
<td valign="top" align="center">2.2</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flhE</td>
<td valign="top" align="center">8</td>
<td/>
<td valign="top" align="center">2.2</td>
<td/>
<td valign="top" align="left">Flagellar protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flgA</td>
<td valign="top" align="center">134</td>
<td/>
<td valign="top" align="center">2.4</td>
<td/>
<td valign="top" align="left">Flagellar biosynthesis; assembly of basal-body periplasmic P ring</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliD</td>
<td valign="top" align="center">17</td>
<td/>
<td valign="top" align="center">2.5</td>
<td/>
<td valign="top" align="left">Flag. biosynth; filament capping protein; enables filament assembly</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliI</td>
<td valign="top" align="center">39</td>
<td/>
<td valign="top" align="center">2.5</td>
<td/>
<td valign="top" align="left">Flagellum-specific ATP synthase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliK</td>
<td valign="top" align="center">168</td>
<td/>
<td valign="top" align="center">3.4</td>
<td/>
<td valign="top" align="left">Flagellar hook-length control protein</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Protection</td>
<td valign="top" align="left">ompF</td>
<td valign="top" align="center">45,769</td>
<td/>
<td valign="top" align="center">&#x02212;7.3</td>
<td/>
<td valign="top" align="left">Outer membrane protein 1a</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">kdpE</td>
<td valign="top" align="center">132</td>
<td/>
<td valign="top" align="center">2.1</td>
<td/>
<td valign="top" align="left">Regulator of kdp operon</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">sbmA</td>
<td valign="top" align="center">231</td>
<td/>
<td valign="top" align="center">2.1</td>
<td/>
<td valign="top" align="left">Sensitivity to microcin B17. possibly envelop protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gfcC</td>
<td valign="top" align="center">9</td>
<td/>
<td valign="top" align="center">2.3</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">sdiA</td>
<td valign="top" align="center">295</td>
<td/>
<td valign="top" align="center">2.5</td>
<td/>
<td valign="top" align="left">Regulatory protein sdiA</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">etk</td>
<td valign="top" align="center">23</td>
<td/>
<td valign="top" align="center">2.7</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">etp</td>
<td valign="top" align="center">26</td>
<td/>
<td valign="top" align="center">2.7</td>
<td/>
<td valign="top" align="left">Putative phosphatase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">yadK</td>
<td valign="top" align="center">10</td>
<td/>
<td valign="top" align="center">2.7</td>
<td/>
<td valign="top" align="left">Protein yadK</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ybcL</td>
<td valign="top" align="center">84</td>
<td/>
<td valign="top" align="center">3.0</td>
<td/>
<td valign="top" align="left">Protein ybcL precursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gfcE</td>
<td valign="top" align="center">10</td>
<td/>
<td valign="top" align="center">3.1</td>
<td/>
<td valign="top" align="left">Putative function in exopolysaccharide production</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gfcD</td>
<td valign="top" align="center">553</td>
<td/>
<td valign="top" align="center">3.9</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ycbQ</td>
<td valign="top" align="center">8</td>
<td/>
<td valign="top" align="center">4.3</td>
<td/>
<td valign="top" align="left">Putative fimbrial-like protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gfcA</td>
<td valign="top" align="center">278</td>
<td/>
<td valign="top" align="center">4.6</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">sulA</td>
<td valign="top" align="center">2,130</td>
<td/>
<td valign="top" align="center">5.4</td>
<td/>
<td valign="top" align="left">Suppressor of lon; inhibits cell division and ftsZ ring formation</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">recA</td>
<td valign="top" align="center">1,662</td>
<td/>
<td valign="top" align="center">6.0</td>
<td/>
<td valign="top" align="left">DNA strand exchange and renaturation. DNA-dep ATPase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">lexA</td>
<td valign="top" align="center">489</td>
<td/>
<td valign="top" align="center">6.3</td>
<td/>
<td valign="top" align="left">Regulator for SOS</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">bhsA</td>
<td valign="top" align="center">241</td>
<td/>
<td valign="top" align="center">8.8</td>
<td/>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Secretion</td>
<td valign="top" align="left">tir</td>
<td valign="top" align="center">39</td>
<td/>
<td valign="top" align="center">2.2</td>
<td/>
<td valign="top" align="left">Putative translocated intimin receptor protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">escJ</td>
<td valign="top" align="center">15</td>
<td/>
<td valign="top" align="center">2.5</td>
<td/>
<td valign="top" align="left">escJ</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">escN</td>
<td valign="top" align="center">15</td>
<td/>
<td valign="top" align="center">2.8</td>
<td/>
<td valign="top" align="left">escN</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">espB</td>
<td valign="top" align="center">8</td>
<td/>
<td valign="top" align="center">2.8</td>
<td/>
<td valign="top" align="left">Secreted protein EspB</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">sepQ</td>
<td valign="top" align="center">3</td>
<td/>
<td valign="top" align="center">3.1</td>
<td/>
<td valign="top" align="left">sepQ</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">sepZ</td>
<td valign="top" align="center">11</td>
<td/>
<td valign="top" align="center">3.3</td>
<td/>
<td valign="top" align="left">sepZ</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">eae</td>
<td valign="top" align="center">20</td>
<td/>
<td valign="top" align="center">3.4</td>
<td/>
<td valign="top" align="left">Intimin adherence protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">escU</td>
<td valign="top" align="center">49</td>
<td/>
<td valign="top" align="center">3.6</td>
<td/>
<td valign="top" align="left">escU</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Siderophore</td>
<td valign="top" align="left">entB</td>
<td valign="top" align="center">345</td>
<td/>
<td valign="top" align="center">&#x02212;3.6</td>
<td/>
<td valign="top" align="left">2.3-dihydro-2.3-dihydroxybenzoate synthetase. isochroismatase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">entF</td>
<td valign="top" align="center">6</td>
<td/>
<td valign="top" align="center">&#x02212;3.5</td>
<td/>
<td valign="top" align="left">Enterobactin synthetase component F</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">iucC</td>
<td valign="top" align="center">867</td>
<td/>
<td valign="top" align="center">&#x02212;3.5</td>
<td/>
<td valign="top" align="left">IucC protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">entA</td>
<td valign="top" align="center">262</td>
<td/>
<td valign="top" align="center">&#x02212;3.4</td>
<td/>
<td valign="top" align="left">2.3-dihydro-2.3-dihydroxybenzoate dehydrogenase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">chuS</td>
<td valign="top" align="center">655</td>
<td/>
<td valign="top" align="center">&#x02212;2.8</td>
<td/>
<td valign="top" align="left">Putative heme/hemoglobin transport protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fepG</td>
<td valign="top" align="center">967</td>
<td/>
<td valign="top" align="center">&#x02212;2.7</td>
<td/>
<td valign="top" align="left">Ferric enterobactin transport protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">iucB</td>
<td valign="top" align="center">365</td>
<td/>
<td valign="top" align="center">&#x02212;2.6</td>
<td/>
<td valign="top" align="left">IucB protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">feoB</td>
<td valign="top" align="center">937</td>
<td/>
<td valign="top" align="center">&#x02212;2.5</td>
<td/>
<td valign="top" align="left">Ferrous iron transport protein B</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">iroE</td>
<td valign="top" align="center">10</td>
<td/>
<td valign="top" align="center">3.7</td>
<td/>
<td valign="top" align="left">IroE protein</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Toxins</td>
<td valign="top" align="left">stx1A</td>
<td valign="top" align="center">22</td>
<td/>
<td valign="top" align="center">2.3</td>
<td/>
<td valign="top" align="left">Shiga-like toxin 1 subunit A encoded within</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">hlyE</td>
<td valign="top" align="center">135</td>
<td/>
<td valign="top" align="center">2.8</td>
<td/>
<td valign="top" align="left">Hemolysin E</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">stx2B</td>
<td valign="top" align="center">6</td>
<td/>
<td valign="top" align="center">3.6</td>
<td/>
<td valign="top" align="left">Shiga-like toxin II B subunit</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">stx1B</td>
<td valign="top" align="center">12</td>
<td/>
<td valign="top" align="center">4.3</td>
<td/>
<td valign="top" align="left">Shiga-like toxin 1 subunit B</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Transcription regulation</td>
<td valign="top" align="left">rfaH</td>
<td valign="top" align="center">384</td>
<td/>
<td valign="top" align="center">2.1</td>
<td/>
<td valign="top" align="left">Transcription act. of lipopolysaccharide core. F pilin. and haemolysin</td>
</tr>
<tr>
<td valign="top" align="left">Adhesin</td>
<td valign="top" align="left">fimC</td>
<td valign="top" align="center">26</td>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="center">3.5</td>
<td valign="top" align="left">Periplasmic chaperone. required for type 1 fimbriae</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimI</td>
<td valign="top" align="center">39</td>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="center">3.4</td>
<td valign="top" align="left">Fimbrial protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimH</td>
<td valign="top" align="center">36</td>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="center">3.6</td>
<td valign="top" align="left">Minor fimbrial subunit. D-mannose specific adhesin</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimD</td>
<td valign="top" align="center">25</td>
<td/>
<td valign="top" align="center">2.2</td>
<td valign="top" align="center">2.9</td>
<td valign="top" align="left">Outer membrane protein; export and assembly of type 1 fimbriae</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimA</td>
<td valign="top" align="center">126</td>
<td/>
<td valign="top" align="center">2.0</td>
<td valign="top" align="center">2.3</td>
<td valign="top" align="left">Major type 1 subunit fimbrin</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">csgC</td>
<td valign="top" align="center">19</td>
<td/>
<td valign="top" align="center">2.6</td>
<td valign="top" align="center">2.0</td>
<td valign="top" align="left">Putative curli production protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimG</td>
<td valign="top" align="center">27</td>
<td/>
<td valign="top" align="center">2.8</td>
<td valign="top" align="center">2.5</td>
<td valign="top" align="left">Fimbrial morphology</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fimF</td>
<td valign="top" align="center">8</td>
<td/>
<td valign="top" align="center">3.6</td>
<td valign="top" align="center">3.3</td>
<td valign="top" align="left">FimF protein precursor</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">LPS synthesis</td>
<td valign="top" align="left">yijP</td>
<td valign="top" align="center">4,354</td>
<td/>
<td valign="top" align="center">&#x02212;2.3</td>
<td valign="top" align="center">&#x02212;3.8</td>
<td valign="top" align="left">Protein yijP</td>
</tr>
<tr>
<td valign="top" align="left">Metabolism</td>
<td valign="top" align="left">glnA</td>
<td valign="top" align="center">8,617</td>
<td/>
<td valign="top" align="center">&#x02212;86.0</td>
<td valign="top" align="center">&#x02212;15.1</td>
<td valign="top" align="left">Glutamine synthetase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ilvD</td>
<td valign="top" align="center">3,921</td>
<td/>
<td valign="top" align="center">&#x02212;11.3</td>
<td valign="top" align="center">&#x02212;8.2</td>
<td valign="top" align="left">Dihydroxy-acid dehydratase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">serA</td>
<td valign="top" align="center">2,494</td>
<td/>
<td valign="top" align="center">&#x02212;9.6</td>
<td valign="top" align="center">&#x02212;3.7</td>
<td valign="top" align="left">D-3-phosphoglycerate dehydrogenase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">tdcE</td>
<td valign="top" align="center">123</td>
<td/>
<td valign="top" align="center">&#x02212;3.6</td>
<td valign="top" align="center">3.7</td>
<td valign="top" align="left">Keto-acid formate acetyltransferase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">trpB</td>
<td valign="top" align="center">573</td>
<td/>
<td valign="top" align="center">&#x02212;3.0</td>
<td valign="top" align="center">&#x02212;2.5</td>
<td valign="top" align="left">Tryptophan synthase. beta protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">kbaZ</td>
<td valign="top" align="center">9</td>
<td/>
<td valign="top" align="center">2.3</td>
<td valign="top" align="center">16.0</td>
<td valign="top" align="left">Putative tagatose 6-phosphate kinase 2</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">pitB</td>
<td valign="top" align="center">26</td>
<td/>
<td valign="top" align="center">2.8</td>
<td valign="top" align="center">3.2</td>
<td valign="top" align="left">Low-affinity phosphate transport</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">aer</td>
<td valign="top" align="center">29</td>
<td/>
<td valign="top" align="center">2.8</td>
<td valign="top" align="center">3.3</td>
<td valign="top" align="left">Aerotaxis sensor receptor. flavoprotein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">trxC</td>
<td valign="top" align="center">276</td>
<td/>
<td valign="top" align="center">3.5</td>
<td valign="top" align="center">3.3</td>
<td valign="top" align="left">Thioredoxin 2</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Motility</td>
<td valign="top" align="left">fliJ</td>
<td valign="top" align="center">13</td>
<td/>
<td valign="top" align="center">3.4</td>
<td valign="top" align="center">2.3</td>
<td valign="top" align="left">Flagellar fliJ protein</td>
</tr>
<tr>
<td valign="top" align="left">Protection</td>
<td valign="top" align="left">ompW</td>
<td valign="top" align="center">4,714</td>
<td/>
<td valign="top" align="center">&#x02212;9.1</td>
<td valign="top" align="center">2.6</td>
<td valign="top" align="left">Outer membrane protein W precursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">matB</td>
<td valign="top" align="center">614</td>
<td/>
<td valign="top" align="center">&#x02212;2.5</td>
<td valign="top" align="center">2.2</td>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">evgS</td>
<td valign="top" align="center">526</td>
<td/>
<td valign="top" align="center">&#x02212;2.2</td>
<td valign="top" align="center">&#x02212;2.9</td>
<td valign="top" align="left">Putative sensor for regulator EvgA</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ECs0850</td>
<td valign="top" align="center">5</td>
<td/>
<td valign="top" align="center">4.6</td>
<td valign="top" align="center">2.2</td>
<td valign="top" align="left">Hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">manB</td>
<td valign="top" align="center">11</td>
<td/>
<td valign="top" align="center">8.5</td>
<td valign="top" align="center">2.3</td>
<td valign="top" align="left">Phosphomannomutase</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Siderophore</td>
<td valign="top" align="left">yjjQ</td>
<td valign="top" align="center">68</td>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="center">2.4</td>
<td valign="top" align="left">putative regulator</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="2">Transcription regulation</td>
<td valign="top" align="left">rpoB</td>
<td valign="top" align="center">12,927</td>
<td/>
<td valign="top" align="center">&#x02212;2.3</td>
<td valign="top" align="center">&#x02212;4.5</td>
<td valign="top" align="left">RNA polymerase. beta subunit</td>
</tr>
<tr>
<td valign="top" align="left">rpoA</td>
<td valign="top" align="center">68,440</td>
<td/>
<td valign="top" align="center">&#x02212;2.3</td>
<td valign="top" align="center">&#x02212;3.7</td>
<td valign="top" align="left">RNA polymerase. alpha subunit</td>
</tr>
<tr>
<td valign="top" align="left">Adhesin</td>
<td valign="top" align="left">ppdD</td>
<td valign="top" align="center">21</td>
<td/>
<td/>
<td valign="top" align="center">2.3</td>
<td valign="top" align="left">Prelipin peptidase dependent protein</td>
</tr>
<tr>
<td valign="top" align="left">LPS synthesis</td>
<td valign="top" align="left">rfaS</td>
<td valign="top" align="center">12,88</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;4.3</td>
<td valign="top" align="left">Lipopolysaccharide core biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">rfaP</td>
<td valign="top" align="center">3,909</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;3.8</td>
<td valign="top" align="left">LPS core biosynthesis; phosphorylation of core heptose</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">rfaZ</td>
<td valign="top" align="center">2,091</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;3.0</td>
<td valign="top" align="left">Lipopolysaccharide core biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">rfaY</td>
<td valign="top" align="center">1,690</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.5</td>
<td valign="top" align="left">Lipopolysaccharide core biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">waaU</td>
<td valign="top" align="center">999</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.1</td>
<td valign="top" align="left">Probably hexose transferase; lipopolysaccharide core biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">rfaG</td>
<td valign="top" align="center">1,009</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.0</td>
<td valign="top" align="left">Lipopolysaccharide core biosynthesis protein rfaG</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Metabolism</td>
<td valign="top" align="left">eda</td>
<td valign="top" align="center">3,246</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;3.1</td>
<td valign="top" align="left">2-keto-3-deoxygluc 6-phos aldo and 2-keto-4-hydroxyglut aldo</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">tktA</td>
<td valign="top" align="center">2,823</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.2</td>
<td valign="top" align="left">Transketolase 1 isozyme</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">dsbA</td>
<td valign="top" align="center">27,226</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.1</td>
<td valign="top" align="left">Protein disulfide isomerase I. essential for cytochrome c synthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">prfB</td>
<td valign="top" align="center">3,054</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.0</td>
<td valign="top" align="left">Peptide chain release factor 2</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gnsA</td>
<td valign="top" align="center">3,461</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.0</td>
<td valign="top" align="left">Predicted regulator of phosphatidylethanolamine synthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">yjhS</td>
<td valign="top" align="center">37</td>
<td/>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">agaA</td>
<td valign="top" align="center">113</td>
<td/>
<td/>
<td valign="top" align="center">2.5</td>
<td valign="top" align="left">Putative N-acetylgalactosamine-6-phosphate deacetylase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">agaC</td>
<td valign="top" align="center">42</td>
<td/>
<td/>
<td valign="top" align="center">2.7</td>
<td valign="top" align="left">PTS system N-acetylgalactosamine-specific IIC component 1</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">dctA</td>
<td valign="top" align="center">3,224</td>
<td/>
<td/>
<td valign="top" align="center">3.2</td>
<td valign="top" align="left">Uptake of C4-dicarboxylic acids</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">astA</td>
<td valign="top" align="center">93</td>
<td/>
<td/>
<td valign="top" align="center">3.6</td>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">lacZ</td>
<td valign="top" align="center">20</td>
<td/>
<td/>
<td valign="top" align="center">3.7</td>
<td valign="top" align="left">Beta-galactosidase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gatZ</td>
<td valign="top" align="center">18</td>
<td/>
<td/>
<td valign="top" align="center">4.1</td>
<td valign="top" align="left">Putative tagatose 6-phosphate kinase 1</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">gatB</td>
<td valign="top" align="center">15</td>
<td/>
<td/>
<td valign="top" align="center">5.0</td>
<td valign="top" align="left">Galactitol-specific enzyme IIB of phosphotransferase system</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">agaS</td>
<td valign="top" align="center">72</td>
<td/>
<td/>
<td valign="top" align="center">5.3</td>
<td valign="top" align="left">Putative tagatose-6-phosphate aldose/ketose isomerase</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">agaB</td>
<td valign="top" align="center">32</td>
<td/>
<td/>
<td valign="top" align="center">7.0</td>
<td valign="top" align="left">PTS system. cytopl. N-acetylgalactosamine-spec IIB component 1</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ulaB</td>
<td valign="top" align="center">27</td>
<td/>
<td/>
<td valign="top" align="center">7.2</td>
<td valign="top" align="left">Putative transport protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ulaC</td>
<td valign="top" align="center">86</td>
<td/>
<td/>
<td valign="top" align="center">8.6</td>
<td valign="top" align="left">Putative PTS system enzyme II A component</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">ulaA</td>
<td valign="top" align="center">76</td>
<td/>
<td/>
<td valign="top" align="center">11.2</td>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">agaW</td>
<td valign="top" align="center">40</td>
<td/>
<td/>
<td valign="top" align="center">18.1</td>
<td valign="top" align="left">PTS system N-acetylgalactosameine-specific IIC component 2</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">agaV</td>
<td valign="top" align="center">19</td>
<td/>
<td/>
<td valign="top" align="center">18.9</td>
<td valign="top" align="left">PTS system. cytopl. N-acetylgalactosamine-spec IIB component 2</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">kbaY</td>
<td valign="top" align="center">19</td>
<td/>
<td/>
<td valign="top" align="center">28.0</td>
<td valign="top" align="left">Tagatose-bisphosphate aldolase 2</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Motility</td>
<td valign="top" align="left">fliT</td>
<td valign="top" align="center">31</td>
<td/>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="left">Flagellar biosynthesis; repressor of class 3a and 3b operons</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flgJ</td>
<td valign="top" align="center">29</td>
<td/>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="left">Flagellar biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliO</td>
<td valign="top" align="center">11</td>
<td/>
<td/>
<td valign="top" align="center">2.1</td>
<td valign="top" align="left">Flagellar protein fliO</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliL</td>
<td valign="top" align="center">23</td>
<td/>
<td/>
<td valign="top" align="center">2.2</td>
<td valign="top" align="left">Flagellar biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flgH</td>
<td valign="top" align="center">20</td>
<td/>
<td/>
<td valign="top" align="center">2.2</td>
<td valign="top" align="left">Flagellar biosynthesis. basal-body outer-membrane L</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flhB</td>
<td valign="top" align="center">38</td>
<td/>
<td/>
<td valign="top" align="center">2.3</td>
<td valign="top" align="left">Putative part of export apparatus for flagellar proteins</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">flgB</td>
<td valign="top" align="center">24</td>
<td/>
<td/>
<td valign="top" align="center">2.3</td>
<td valign="top" align="left">Flagellar biosynthesis. cell-proximal portion of basal-body rod</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliE</td>
<td valign="top" align="center">37</td>
<td/>
<td/>
<td valign="top" align="center">2.7</td>
<td valign="top" align="left">Flagellar biosynthesis; basal-body component</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliF</td>
<td valign="top" align="center">27</td>
<td/>
<td/>
<td valign="top" align="center">2.8</td>
<td valign="top" align="left">Flagellar biosynthesis; basal-body MS</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">lfhA</td>
<td valign="top" align="center">8</td>
<td/>
<td/>
<td valign="top" align="center">3.1</td>
<td valign="top" align="left">Flagellar biosynthesis</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliP</td>
<td valign="top" align="center">11</td>
<td/>
<td/>
<td valign="top" align="center">3.3</td>
<td valign="top" align="left">Flagellar biosynthetic protein fliP precursor</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">fliQ</td>
<td valign="top" align="center">21</td>
<td/>
<td/>
<td valign="top" align="center">4.9</td>
<td valign="top" align="left">Flagellar biosynthesis</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Protection</td>
<td valign="top" align="left">kpsC</td>
<td valign="top" align="center">986</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;3.4</td>
<td valign="top" align="left">KpsC protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">bamA</td>
<td valign="top" align="center">6,961</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;3.3</td>
<td valign="top" align="left">orf. hypothetical protein</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">evgS</td>
<td valign="top" align="center">526</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.9</td>
<td valign="top" align="left">putative sensor for regulator EvgA</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">degP</td>
<td valign="top" align="center">6,718</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.6</td>
<td valign="top" align="left">Periplasmic serine protease Do; heat shock protein HtrA</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">kpsM</td>
<td valign="top" align="center">3,290</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;2.2</td>
<td valign="top" align="left">KpsM protein</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td valign="top" align="left">Transcription regulation</td>
<td valign="top" align="left">fis</td>
<td valign="top" align="center">61,722</td>
<td/>
<td/>
<td valign="top" align="center">&#x02212;3.9</td>
<td valign="top" align="left">Site-specific DNA inversion stimulation factor; DNA-binding protein</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>In order to confirm the microarray results, real-time qPCR was carried out on seven genes belonging to the functional categories Adhesion (<italic>FimAH</italic>), Protection (<italic>ibpAB</italic>), and Siderophore (<italic>chuAT, sitB</italic>) that were significantly altered compared to ESBL019 Coliform. In agreement with the microarray, a significant upregulation of <italic>FimAH</italic> was observed in ESBL019 Filamented and ESBL019 Reverted state compared to ESBL019 Coliform (Table <xref ref-type="table" rid="T2">2</xref>). In addition, <italic>ibpAB</italic> was observed to be significant upregulated in all the three different states compared to ESBL019 Coliform, as shown by the microarray data. We also found that <italic>chuAT, sitB</italic> were significantly downregulated in ESBL019 Transition and ESBL019 Filamented state compared to ESBL019 Coliform (Table <xref ref-type="table" rid="T2">2</xref>). However, this was not observed to be true for the ESBL019 Reverted state.</p>
<table-wrap position="float" id="T3">
<label>Table 2</label>
<caption><p>Quantitative real-time PCR data for ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted compared to ESBL019 Coliform.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Gene</bold></th>
<th/>
<th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;"><bold>Fold change vs. ESBL019 coliform</bold></th>
<th valign="top" align="left"><bold>Description</bold></th>
</tr>
<tr>
<th/>
<th valign="top" align="center"><bold>ESBL019 transition</bold></th>
<th valign="top" align="center"><bold>ESBL019 filamentous</bold></th>
<th valign="top" align="center"><bold>ESBL019 reverted</bold></th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">FimA</td>
<td valign="top" align="center">&#x02212;1.2 &#x000B1; 0.86<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">15 &#x000B1; 3.1<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">8.5 &#x000B1; 2.1<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="left">Major type 1 subunit fimbrin</td>
</tr>
<tr>
<td valign="top" align="left">FimH</td>
<td valign="top" align="center">&#x02212;1.1 &#x000B1; 0.74<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">10 &#x000B1; 1.8<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">11 &#x000B1; 2.3<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="left">Minor fimbrial subunit. D-mannose specific adhesin</td>
</tr>
<tr>
<td valign="top" align="left">ibpA</td>
<td valign="top" align="center">5.3 &#x000B1; 0.90<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">230 &#x000B1; 49<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">22 &#x000B1; 3.7<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="left">Heat shock protein</td>
</tr>
<tr>
<td valign="top" align="left">ibpB</td>
<td valign="top" align="center">7.2 &#x000B1; 1.5<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">330 &#x000B1; 80<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">130 &#x000B1; 33<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="left">Heat shock protein</td>
</tr>
<tr>
<td valign="top" align="left">chuA</td>
<td valign="top" align="center">&#x02212;6.3 &#x000B1; 1.2<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">&#x02212;1.6 &#x000B1; 0.1<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">0.90 &#x000B1; 1.0</td>
<td valign="top" align="left">Putative Periplasmic binding protein</td>
</tr>
<tr>
<td valign="top" align="left">chuT</td>
<td valign="top" align="center">&#x02212;15 &#x000B1; 3.2<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">&#x02212;4.4 &#x000B1; 1.5<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">1.1 &#x000B1; 1.0</td>
<td valign="top" align="left">Outer membrane heme/hemoglobin receptor</td>
</tr>
<tr>
<td valign="top" align="left">sitB</td>
<td valign="top" align="center">&#x02212;11 &#x000B1; 1.6<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">&#x02212;5.4 &#x000B1; 1.6<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td valign="top" align="center">0.71 &#x000B1; 0.82</td>
<td valign="top" align="left">SitB protein</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>n &#x0003D; 3&#x02013;4</italic>.</p>
<fn id="TN1">
<label>a</label>
<p><italic>Significantly altered genes compared to ESBL019 Coliform</italic>.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec>
<title>Fimbriae agglutination</title>
<p>We proceeded with evaluating the phenotypical presence and functionality of the type-1 fimbriae and P-fimbriae in the different morphological states of ESBL019. Yeast agglutination confirmed that all the morphological states of ESBL019 expressed functional type-1 fimbriae (Figures <xref ref-type="fig" rid="F4">4B&#x02013;E</xref>) compared to only yeast (Figure <xref ref-type="fig" rid="F4">4A</xref>). The aggregation pattern between the rod shaped (ESBL019 Coliform and ESBL019 Reverted) and the elongated ESBL019 (ESBL019 Transition and ESBL019 Filamented) morphologies were strikingly different. The yeast was bound along the elongated bacteria and gave a more uniform aggregation (Figures <xref ref-type="fig" rid="F4">4C,D</xref>), while the rod shaped bacteria formed large isolated yeast aggregates (Figures <xref ref-type="fig" rid="F4">4B,E</xref>). Human Erythrocytes of blood group P were used to evaluate the P-fimbriae expression. All the morphological states of ESBL019 expressed functional P-fimbriae (Figures <xref ref-type="fig" rid="F4">4G&#x02013;J</xref>) compared to only erythrocytes (Figure <xref ref-type="fig" rid="F4">4F</xref>). We also observed an increased aggregation by the ESBL019 Transition (Figure <xref ref-type="fig" rid="F4">4H</xref>), ESBL019 Filamented (Figure <xref ref-type="fig" rid="F4">4I</xref>) and ESBL019 Reverted (Figure <xref ref-type="fig" rid="F4">4J</xref>) states compared to ESBL019 Coliform (Figure <xref ref-type="fig" rid="F4">4G</xref>).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>Fimbriae aggregation and TNF-&#x003B1; release from HBEP cells infected with the different morphologies of ESBL019. Type-1 fimbriae functionality was assessed by yeast agglutination without <bold>(A)</bold> or with ESBL019 Coliform <bold>(B)</bold>, ESBL019 Transition <bold>(C)</bold>, ESBL019 Filamented <bold>(D)</bold> and ESBL019 Reverted <bold>(E)</bold> using light microscopy. P-fimbriae functionality was assessed by P-positive human erythrocyte agglutination without <bold>(F)</bold> or with ESBL019 Coliform <bold>(G)</bold>, ESBL019 Transition <bold>(H)</bold>, ESBL019 Filamented <bold>(I)</bold>, and ESBL019 Reverted <bold>(J)</bold> using light microscopy. Scale bare: 200 &#x003BC;m. TNF-&#x003B1; release from HBEP cells stimulated with ESBL019 Coliform, ESBL019 Transition, ESBL019 Filamented and ESBL019 Reverted (MOI10) for 4 h in the presence (Transition, Filamented) or absence (Coliform and Reverted) of ceftibuten <bold>(K)</bold>. Data are presented as mean &#x000B1; SEM of <italic>n</italic> &#x0003D; 4 independent experiments. Asterisks denote statistical significance <sup>&#x0002A;&#x0002A;</sup><italic>p</italic> &#x0003C; 0.01, <sup>&#x0002A;&#x0002A;&#x0002A;</sup><italic>p</italic> &#x0003C; 0.001.</p></caption>
<graphic xlink:href="fmicb-08-01058-g0004.tif"/>
</fig>
</sec>
<sec>
<title>Epithelial TNF-&#x003B1; release evoked by the different morphological states</title>
<p>Primary human bladder epithelial cells were stimulated with the different morphological states of ESBL019 to determine their ability to induce the pro-inflammatory cytokine TNF-&#x003B1;. The unstimulated control cells showed no basal release of TNF-&#x003B1; (Figure <xref ref-type="fig" rid="F4">4K</xref>). ESBL019 Coliform and ESBL Filamented were able to induce an increased release of TNF-&#x003B1; compared to the control. ESBL019 Transition induced a significant higher release of TNF-&#x003B1; compared to control (<italic>p</italic> &#x0003C; 0.001), ESBL019 Coliform (<italic>p</italic> &#x0003C; 0.01), ESBL019 Filamented (<italic>p</italic> &#x0003C; 0.01) and ESBL019 Reverted (<italic>p</italic> &#x0003C; 0.001). In contrast to the other morphological states of ESBL019, ESBL019 Reverted did not induce any release of TNF-&#x003B1; from the bladder epithelial cells. Taken together, the different morphological states of ESBL019 induce a diverse TNF-&#x003B1; release from bladder epithelial cells.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Global gene expression profiling of the different morphological states of ESBL019 demonstrated a significant transcriptional alteration of a large number of genes. In the ESBL019 Transition state, close to 7% of the entities on the array were altered, 32% for ESBL019 Filamented and 19% for ESBL019 Reverted. Thus, it appears that the morphological plasticity of UPEC is associated with an extensive flux in the transcriptome of the bacteria and especially in the filamented state. To the best of our knowledge, this is the first study that investigates changes in global gene expression patterns and in virulence factor associated genes in ESBL-producing UPEC during the morphologic transitions induced by ineffective antibiotics. Importantly, all experiments were conducted in the presence of human primary bladder epithelial cells to mimic the <italic>in vivo</italic> host-pathogen interactions in a physiologically relevant manner.</p>
<p>The majority of the identified changes in gene ontologies and pathways were associated with metabolic functions. Many metabolic functions are not specific for pathogens and their role in infection fitness remains therefore more or less unexplored (Subashchandrabose and Mobley, <xref ref-type="bibr" rid="B35">2015</xref>). In the ESBL019 Transition state, we observed that genes associated with the tricarboxylic acid cycle (TCA) and glucogenic amino acid (arginine, glutamate, glutamine, and proline) metabolism were in majority downregulated. We also found that the gene <italic>dctA</italic>, which encodes for the C4-dicarboxylate transporter that is responsible for the uptake of fumarate, succinate and malate was downregulated. Previous studies have shown that gluconeogenesis and the TCA cycle, but not Entner-Doudoroff, glycolysis or pentose-phosphate pathways are important for the fitness of UPEC during <italic>in vivo</italic> experimental UTI (Alteri et al., <xref ref-type="bibr" rid="B1">2009</xref>). Genes associated with amino acid metabolism, such as <italic>dctA, serA</italic> (L-serine biosynthesis), <italic>ilvD</italic> (isoleucine and valine biosynthesis), <italic>trpB</italic> (tryptophan synthase beta), <italic>glnA</italic> (catalyzing conversion of glutamate to glutamine) and <italic>dppA</italic> (dipeptide transporter) were observed to be downregulated in the ESBL019 Filamented state. It has been shown that UPEC grown in urine utilizes primarily peptides and amino acids as carbon sources instead of glucose (Alteri et al., <xref ref-type="bibr" rid="B1">2009</xref>). We also observed that several sugar transporter associated genes such as <italic>gatC</italic> and <italic>ycjV</italic> were upregulated in the filamented state, which could lead to an increased acquisition of carbon sources. In the ESBL019 Reverted state, glucose and xylose degradation, glycolysis, Entner-Doudoroff, NAD biosynthesis and gluconeogenesis pathways were downregulated. We also found, in accordance with the filamented state, that <italic>glnA, ilvD</italic>, and <italic>serA</italic> were downregulated. In addition, an increase in genes associated with replenishing TCA cycle intermediates (<italic>dctA</italic> and <italic>astA</italic>), sugar transporters (<italic>agaABCVW</italic>), L-ascorbate transport (<italic>ulaABC</italic>) and degradation of other carbon sources like lactose (l<italic>acZ</italic>) was observed. It has recently been shown that beta-galactosidase (l<italic>acZ</italic>) may play an important role in intracellular UPEC growth and IBC maturation (Conover et al., <xref ref-type="bibr" rid="B10">2016</xref>). An interesting finding in the ESBL019 Reverted state was the downregulation of genes associated with transcription, translation, ribosome biosynthesis and tRNA charging. Taken together, these data demonstrates that all three morphological states of UPEC are associated with a decreased energy-yielding cell metabolism, suggesting that survival rather than growth is prioritized. Knowledge of these metabolic shifts could contribute to finding new therapeutic targets to limit the bacteria&#x00027;s ability to acquire alternative carbon sources.</p>
<p>Metals such as iron are essential for bacterial life and the low concentration of soluble iron in the urinary tract is regarded as a limiting factor for UPEC growth (Roos et al., <xref ref-type="bibr" rid="B30">2006</xref>). Consequently, it has been shown that iron acquisition is important for UPEC survival and pathogenicity (Subashchandrabose and Mobley, <xref ref-type="bibr" rid="B35">2015</xref>). UPEC can acquire iron through several mechanisms such as siderophores (ferric iron chelators), ferrous iron transporters and heme through outer membrane receptors (Cho et al., <xref ref-type="bibr" rid="B9">2008</xref>). We observed that the iron acquisition systems in all the morphological states of UPEC changed significantly. Genes involved in the enterobactin system (<italic>entABF, fepABE</italic>), heme system (<italic>chuST</italic>) and ferrous iron uptake (<italic>sitB</italic>) were downregulated in all the three morphological states. However, genes in the aerobactin system (<italic>iucAC</italic>) were downregulated in the ESBL019 Transition and ESBL019 Filamented state but not in the ESBL019 Reverted state. The salmochelin siderophore system (<italic>iroEN</italic>) was upregulated in all the three morphological states. qPCR analysis confirmed that <italic>chuAT</italic> and <italic>sitB</italic> were significantly downregulated in ESBL019 Transition and ESBL019 Filamented state, but not in the ESBL019 Reverted state compared to ESBL019 Coliform. The iron acquisition systems in UPEC have been demonstrated to be redundant, but individual systems have been shown to play key roles in fitness and pathogenicity in different regions of the urinary tract (Garcia et al., <xref ref-type="bibr" rid="B16">2011</xref>). Aerobactin receptors have been shown to significantly contribute to <italic>in vivo</italic> fitness and they are critical for UPEC virulence (Garcia et al., <xref ref-type="bibr" rid="B16">2011</xref>). It was recently shown that the virulence associated with iron acquisition could be partially due to modulation of amino acid metabolism (Su et al., <xref ref-type="bibr" rid="B33">2016</xref>). Taken together, these data show that the iron acquisition systems in UPEC are altered during morphological shifts, mainly downregulated, but the redundancy in the systems may contribute to preserving <italic>in vivo</italic> fitness. In addition, the lack of change in the aerobactin system, one of the key siderophores system in uropathogenicity, may indicate that the reverted morphology maintains virulence in the life cycle of UPEC.</p>
<p>During colonization of the urinary tract, UPEC utilizes different adhesion molecules (like fimbriae) to adhere and invade the epithelial cells in order to persist in the urinary tract (Subashchandrabose and Mobley, <xref ref-type="bibr" rid="B35">2015</xref>). The P-fimbriae encoding genes (<italic>pap</italic>) were upregulated in all the three different morphological states of ESBL019 and we also observed an increased phenotypic expression by agglutination in all the different morphological states compared to ESBL019 Coliform. The P-fimbriae is associated with the pathogenicity of ascending UTI and pyelonephritis (Frendeus et al., <xref ref-type="bibr" rid="B15">2001</xref>). The type-1 fimbriae associated genes (<italic>fim</italic>), which play an important role in adhesion, invasion, IBC, and biofilm formation during cystitis (Flores-Mireles et al., <xref ref-type="bibr" rid="B13">2015</xref>) were upregulated in ESBL019 Filamented and ESBL019 Reverted, but no changes were observed in ESBL019 Transition state. Consistent with the microarray data, <italic>fimAH</italic> were markedly upregulated in the Filamented and Reverted state based on qPCR data. We confirmed phenotypically functional type-1 fimbriae in all the different states by yeast agglutination assays. This indicates that the morphological plasticity of UPEC does not compromise on adhesion factors important for colonizing the urinary tract. We hypothesize that the observed upregulation of P-and type-1 fimbriae associated genes is a mechanism to persist in the urinary tract especially after the bacteria emerge from the IBC in a filamented form. Taken together, our results show that all UPEC morphologies maintain fimbrial expression, which could promote persistence and colonization of the urinary tract.</p>
<p>Ascendance from the bladder to the kidneys is an important virulence trait of UPEC associated with motility and flagella expression (Pichon et al., <xref ref-type="bibr" rid="B27">2009</xref>). Studies of morphological plasticity of ESBL019 showed only one significantly upregulated flagellin gene in the ESBL019 Transition state (<italic>fliC</italic>), but many flagellin genes were both up-and downregulated in the ESBL019 Filamented state. In the ESBL019 Reverted state, all the significantly altered genes were upregulated. These results indicate that morphological plasticity is associated with altered flagellin gene expression, but additional functional experiments are needed to assess the effects on motility.</p>
<p>We and others have shown that filamentation of <italic>E. coli</italic> is associated with a rapid production and release of endotoxins (Gould and MacKenzie, <xref ref-type="bibr" rid="B17">1997</xref>; Demirel et al., <xref ref-type="bibr" rid="B12">2015</xref>). Genes associated with LPS biosynthesis were almost unchanged in the ESBL019 Transition state, but all LPS genes were upregulated in the ESBL019 Filamented state. However, the majority of the LPS associated genes were downregulated in the ESBL019 Reverted state. The modulation of LPS synthesis during the morphological shifts could be a compensation mechanism to replenish LPS on the surface of ESBL019, as increased shedding of LPS was observed during the transition state (Demirel et al., <xref ref-type="bibr" rid="B12">2015</xref>). This modulation of LPS could play a part in the pathogenicity of UPEC as LPS modulates pro-inflammatory responses (Bussolati et al., <xref ref-type="bibr" rid="B8">2002</xref>).</p>
<p>The morphological plasticity of ESBL019 showed an alteration in many genes associated with bacterial protection. Genes like <italic>tcpC</italic>, which is associated with inhibition of pro-inflammatory responses (Yadav et al., <xref ref-type="bibr" rid="B38">2010</xref>), was downregulated in all three states. We also observed that the gene encoding for the outer membrane protein <italic>ompT</italic>, which is involved in the resistance of different antimicrobial peptides (Brannon et al., <xref ref-type="bibr" rid="B6">2013</xref>), was upregulated in the transition state, but downregulated in the two other states. The gene encoding ompF, which is a porin for antibiotics, was downregulated in the filamented state and this has been associated with increased antibiotic resistance (Kishii and Takei, <xref ref-type="bibr" rid="B23">2009</xref>). OmpW, which is required for UPECs resistance against phagocytosis (Wu et al., <xref ref-type="bibr" rid="B37">2013</xref>) was downregulated in the filamented state, but upregulated in the reverted state. We have previously shown that filamented UPEC can be successfully phagocytized by neutrophils (Demirel et al., <xref ref-type="bibr" rid="B12">2015</xref>). Related to neutrophil immunity, the <italic>ybcL</italic> gene proposed to inhibit neutrophil migration was upregulated in the ESBL019 Filamented state (Lau et al., <xref ref-type="bibr" rid="B24">2012</xref>). The gene ontology SOS response was enriched in the ESBL019 Filamented state and the associated genes <italic>recA, lexA</italic>, and <italic>sulA</italic> were upregulated. The SOS system is a response to DNA damage and inhibits cell division and septa formation in order to repair the DNA damage (Justice et al., <xref ref-type="bibr" rid="B20">2006</xref>). <italic>sulA</italic> has been shown to mediate UPEC filamentation and this filamentation is associated with increased genetic variability and point mutations that can lead to antibiotic resistance (Bos et al., <xref ref-type="bibr" rid="B4">2015</xref>). The filamented form also showed an upregulation of genes (<italic>tir, esc</italic>, and <italic>sep</italic>) encoding the Type 3 secretion system (T3SS), which is used by bacteria to inject effectors directly into host cell (Subashchandrabose and Mobley, <xref ref-type="bibr" rid="B35">2015</xref>). T3SS genes are traditionally not found in UPEC, but they have recently been reported to be found in some UPEC isolates (Subashchandrabose et al., <xref ref-type="bibr" rid="B34">2013</xref>), although the role during UTI remains to be determined.</p>
<p>We continued with analyzing the TNF-&#x003B1; production from primary bladder epithelial cells induced by the different morphological states. This was done in order to evaluate the biological relevance of the microarray data. The ESBL019 Transition state induced a significant increase in TNF-&#x003B1; production compared to the control and the other morphologies. We have previously shown that the transition state is associated with increased LPS and ATP release, both known to induce pro-inflammatory cytokines from uroepithelial cells (Demirel et al., <xref ref-type="bibr" rid="B12">2015</xref>). The reverted state did not induce TNF-&#x003B1; production and this may give the reverted UPEC an advantage in colonizing the bladder as host cytokine responses are essential for attracting neutrophils (Smart and Casale, <xref ref-type="bibr" rid="B32">1994</xref>). However, it remains to be investigated if the lack of immune activation by the reverted state is due to an inability to induce an immune response or to an active immune suppression. Our agglutination assays showed no reduced fimbriae function to support that the reverted state is unable to induce an immune response. However, several interesting findings, like the downregulation of LPS associated genes in the reverted state, remains to be evaluated.</p>
<p>Together, these results provide insight into the global gene expression patterns of the different morphological states of ESBL019 induced by an ineffective antibiotic. The decreased energy-yielding metabolism and up-regulated adhesion, suggest that survival and persistence in the bladder is priority rather than growth during the morphological plasticity of ESBL-producing UPEC. These findings are also strengthened by the fact that the reverted state did not induce TNF-&#x003B1; release, which gives the bacteria an advantage in colonizing the bladder. Understanding how ineffective antibiotic treatments affect the virulence and metabolism of ESBL-producing UPEC can promote the identification of new therapeutic targets and new adjuvant combination treatments to reduce the prevalence of multiresistant bacteria.</p>
</sec>
<sec id="s5">
<title>Author contributions</title>
<p>ID, RK and KP design the study. ID and RK conducted the experiments. ID, RK, IR, UP, and KP analyzed the data. ID, RK, IR, UP, and KP drafted the article. All authors read and approved the final manuscript.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer JM and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.</p>
</sec>
</sec>
</body>
<back>
<ack><p>We thank Ola Gustafsson, Department of Biology, Lund University for the assistance with the transmission electron microscopy.</p>
</ack>
<sec sec-type="supplementary-material" id="s6">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fmicb.2017.01058/full#supplementary-material">http://journal.frontiersin.org/article/10.3389/fmicb.2017.01058/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table1.DOCX" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table2.DOCX" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table3.DOCX" id="SM3" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.XLSX" id="SM4" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alteri</surname> <given-names>C. J.</given-names></name> <name><surname>Smith</surname> <given-names>S. N.</given-names></name> <name><surname>Mobley</surname> <given-names>H. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Fitness of <italic>Escherichia coli</italic> during urinary tract infection requires gluconeogenesis and the TCA cycle</article-title>. <source>PLoS Pathog.</source> <volume>5</volume>:<fpage>e1000448</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000448</pub-id><pub-id pub-id-type="pmid">19478872</pub-id></citation>
</ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname> <given-names>G. G.</given-names></name> <name><surname>Palermo</surname> <given-names>J. J.</given-names></name> <name><surname>Schilling</surname> <given-names>J. D.</given-names></name> <name><surname>Roth</surname> <given-names>R.</given-names></name> <name><surname>Heuser</surname> <given-names>J.</given-names></name> <name><surname>Hultgren</surname> <given-names>S. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Intracellular bacterial biofilm-like pods in urinary tract infections</article-title>. <source>Science</source> <volume>301</volume>, <fpage>105</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1126/science.1084550</pub-id><pub-id pub-id-type="pmid">12843396</pub-id></citation>
</ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blango</surname> <given-names>M. G.</given-names></name> <name><surname>Mulvey</surname> <given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Persistence of Uropathogenic <italic>Escherichia coli</italic> in the Face of Multiple Antibiotics</article-title>. <source>Antimicrobial. Agents Chemother.</source> <volume>54</volume>, <fpage>1855</fpage>&#x02013;<lpage>1863</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00014-10</pub-id><pub-id pub-id-type="pmid">20231390</pub-id></citation>
</ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname> <given-names>J.</given-names></name> <name><surname>Zhang</surname> <given-names>Q.</given-names></name> <name><surname>Vyawahare</surname> <given-names>S.</given-names></name> <name><surname>Rogers</surname> <given-names>E.</given-names></name> <name><surname>Rosenberg</surname> <given-names>S. M.</given-names></name> <name><surname>Austin</surname> <given-names>R. H.</given-names></name></person-group> (<year>2015</year>). <article-title>Emergence of antibiotic resistance from multinucleated bacterial filaments</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>112</volume>, <fpage>178</fpage>&#x02013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1420702111</pub-id><pub-id pub-id-type="pmid">25492931</pub-id></citation>
</ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bower</surname> <given-names>J. M.</given-names></name> <name><surname>Eto</surname> <given-names>D. S.</given-names></name> <name><surname>Mulvey</surname> <given-names>M. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Covert operations of uropathogenic <italic>Escherichia coli</italic> within the urinary tract</article-title>. <source>Traffic</source> <volume>6</volume>, <fpage>18</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2004.00251.x</pub-id><pub-id pub-id-type="pmid">15569242</pub-id></citation>
</ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brannon</surname> <given-names>J. R.</given-names></name> <name><surname>Thomassin</surname> <given-names>J. L.</given-names></name> <name><surname>Desloges</surname> <given-names>I.</given-names></name> <name><surname>Gruenheid</surname> <given-names>S.</given-names></name> <name><surname>Le Moual</surname> <given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of uropathogenic <italic>Escherichia coli</italic> OmpT in the resistance against human cathelicidin LL-37</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>345</volume>, <fpage>64</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/1574-6968.12185</pub-id><pub-id pub-id-type="pmid">23710656</pub-id></citation>
</ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brolund</surname> <given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Overview of ESBL-producing <italic>Enterobacteriaceae</italic> from a nordic perspective</article-title>. <source>Infect. Ecol. Epidemiol.</source> <volume>4</volume>:<fpage>24555</fpage>. <pub-id pub-id-type="doi">10.3402/iee.v4.24555</pub-id><pub-id pub-id-type="pmid">25317262</pub-id></citation>
</ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bussolati</surname> <given-names>B.</given-names></name> <name><surname>David</surname> <given-names>S.</given-names></name> <name><surname>Cambi</surname> <given-names>V.</given-names></name> <name><surname>Tobias</surname> <given-names>P. S.</given-names></name> <name><surname>Camussi</surname> <given-names>G.</given-names></name></person-group> (<year>2002</year>). <article-title>Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS</article-title>. <source>Int. J. Mol. Med.</source> <volume>10</volume>, <fpage>441</fpage>&#x02013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.10.4.441</pub-id><pub-id pub-id-type="pmid">12239591</pub-id></citation>
</ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname> <given-names>B. K.</given-names></name> <name><surname>Knight</surname> <given-names>E. M.</given-names></name> <name><surname>Barrett</surname> <given-names>C. L.</given-names></name> <name><surname>Palsson</surname> <given-names>B. O.</given-names></name></person-group> (<year>2008</year>). <article-title>Genome-wide analysis of Fis binding in <italic>Escherichia coli</italic> indicates a causative role for A-/AT-tracts</article-title>. <source>Genome Res.</source> <volume>18</volume>, <fpage>900</fpage>&#x02013;<lpage>910</lpage>. <pub-id pub-id-type="doi">10.1101/gr.070276.107</pub-id><pub-id pub-id-type="pmid">18340041</pub-id></citation>
</ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conover</surname> <given-names>M. S.</given-names></name> <name><surname>Hadjifrangiskou</surname> <given-names>M.</given-names></name> <name><surname>Palermo</surname> <given-names>J. J.</given-names></name> <name><surname>Hibbing</surname> <given-names>M. E.</given-names></name> <name><surname>Dodson</surname> <given-names>K. W.</given-names></name> <name><surname>Hultgren</surname> <given-names>S. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Metabolic requirements of <italic>Escherichia coli</italic> in intracellular bacterial communities during urinary tract infection pathogenesis</article-title>. <source>MBio</source> <volume>7</volume>:<fpage>e00104</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00104-16</pub-id><pub-id pub-id-type="pmid">27073089</pub-id></citation>
</ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coque</surname> <given-names>T. M.</given-names></name> <name><surname>Baquero</surname> <given-names>F.</given-names></name> <name><surname>Canton</surname> <given-names>R.</given-names></name></person-group> (<year>2008</year>). <article-title>Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe</article-title>. <source>Euro. Surveill.</source> <volume>13:pii</volume>: <fpage>19044</fpage>. <pub-id pub-id-type="pmid">19021958</pub-id></citation>
</ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demirel</surname> <given-names>I.</given-names></name> <name><surname>Kruse</surname> <given-names>R.</given-names></name> <name><surname>Onnberg</surname> <given-names>A.</given-names></name> <name><surname>Persson</surname> <given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Ceftibuten-induced filamentation of extended spectrum beta lactamase (ESBL)-producing uropathogenic <italic>Escherichia coli</italic> alters host cell responses during an <italic>in vitro</italic> infection</article-title>. <source>Microb. Pathog.</source> <volume>78</volume>, <fpage>52</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2014.11.015</pub-id><pub-id pub-id-type="pmid">25433242</pub-id></citation>
</ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flores-Mireles</surname> <given-names>A. L.</given-names></name> <name><surname>Walker</surname> <given-names>J. N.</given-names></name> <name><surname>Caparon</surname> <given-names>M.</given-names></name> <name><surname>Hultgren</surname> <given-names>S. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Urinary tract infections: epidemiology, mechanisms of infection and treatment options</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>13</volume>, <fpage>269</fpage>&#x02013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3432</pub-id><pub-id pub-id-type="pmid">25853778</pub-id></citation>
</ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foxman</surname> <given-names>B.</given-names></name></person-group> (<year>2003</year>). <article-title>Epidemiology of urinary tract infections: incidence, morbidity, and economic costs</article-title>. <source>Dis. Month</source> <volume>49</volume>, <fpage>53</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1067/mda.2003.7</pub-id><pub-id pub-id-type="pmid">12601337</pub-id></citation>
</ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frendeus</surname> <given-names>B.</given-names></name> <name><surname>Wachtler</surname> <given-names>C.</given-names></name> <name><surname>Hedlund</surname> <given-names>M.</given-names></name> <name><surname>Fischer</surname> <given-names>H.</given-names></name> <name><surname>Samuelsson</surname> <given-names>P.</given-names></name> <name><surname>Svensson</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2001</year>). <article-title><italic>Escherichia coli</italic> P fimbriae utilize the Toll-like receptor 4 pathway for cell activation</article-title>. <source>Mol. Microbiol.</source> <volume>40</volume>, <fpage>37</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2958.2001.02361.x</pub-id><pub-id pub-id-type="pmid">11298274</pub-id></citation>
</ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname> <given-names>E. C.</given-names></name> <name><surname>Brumbaugh</surname> <given-names>A. R.</given-names></name> <name><surname>Mobley</surname> <given-names>H. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Redundancy and specificity of <italic>Escherichia coli</italic> iron acquisition systems during urinary tract infection</article-title>. <source>Infect. Immun.</source> <volume>79</volume>, <fpage>1225</fpage>&#x02013;<lpage>1235</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.01222-10</pub-id><pub-id pub-id-type="pmid">21220482</pub-id></citation>
</ref>
<ref id="B17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname> <given-names>I. M.</given-names></name> <name><surname>MacKenzie</surname> <given-names>F. M.</given-names></name></person-group> (<year>1997</year>). <article-title>The response of Enterobacteriaceae to beta-lactam antibiotics - &#x02018;round forms, filaments and the root of all evil&#x02019;</article-title>. <source>J. Antimicrob. Chemother.</source> <volume>40</volume>, <fpage>495</fpage>&#x02013;<lpage>499</lpage>. <pub-id pub-id-type="doi">10.1093/jac/40.4.495</pub-id><pub-id pub-id-type="pmid">9372417</pub-id></citation>
</ref>
<ref id="B18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname> <given-names>D. J.</given-names></name> <name><surname>Li</surname> <given-names>B. R.</given-names></name> <name><surname>Casper</surname> <given-names>T.</given-names></name> <name><surname>Partida-Sanchez</surname> <given-names>S.</given-names></name> <name><surname>Hunstad</surname> <given-names>D. A.</given-names></name> <name><surname>Hultgren</surname> <given-names>S. J.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Morphological plasticity promotes resistance to phagocyte killing of uropathogenic <italic>Escherichia coli</italic></article-title>. <source>Microb. Infect.</source> <volume>13</volume>, <fpage>426</fpage>&#x02013;<lpage>437</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2010.12.004</pub-id><pub-id pub-id-type="pmid">21182979</pub-id></citation>
</ref>
<ref id="B19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Justice</surname> <given-names>S. S.</given-names></name> <name><surname>Hung</surname> <given-names>C.</given-names></name> <name><surname>Theriot</surname> <given-names>J. A.</given-names></name> <name><surname>Fletcher</surname> <given-names>D. A.</given-names></name> <name><surname>Anderson</surname> <given-names>G. G.</given-names></name> <name><surname>Footer</surname> <given-names>M. J.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Differentiation and developmental pathways of uropathogenic <italic>Escherichia coli</italic> in urinary tract pathogenesis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>101</volume>, <fpage>1333</fpage>&#x02013;<lpage>1338</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0308125100</pub-id><pub-id pub-id-type="pmid">14739341</pub-id></citation>
</ref>
<ref id="B20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Justice</surname> <given-names>S. S.</given-names></name> <name><surname>Hunstad</surname> <given-names>D. A.</given-names></name> <name><surname>Seed</surname> <given-names>P. C.</given-names></name> <name><surname>Hultgren</surname> <given-names>S. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Filamentation by <italic>Escherichia coli</italic> subverts innate defenses during urinary tract infection</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>103</volume>, <fpage>19884</fpage>&#x02013;<lpage>19889</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0606329104</pub-id><pub-id pub-id-type="pmid">17172451</pub-id></citation>
</ref>
<ref id="B21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khandige</surname> <given-names>S.</given-names></name> <name><surname>Asferg</surname> <given-names>C. A.</given-names></name> <name><surname>Rasmussen</surname> <given-names>K. J.</given-names></name> <name><surname>Larsen</surname> <given-names>M. J.</given-names></name> <name><surname>Overgaard</surname> <given-names>M.</given-names></name> <name><surname>Andersen</surname> <given-names>T. E.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>DamX controls reversible cell morphology switching in uropathogenic <italic>Escherichia coli</italic></article-title>. <source>MBio</source> 7:pii: e00642-16. <pub-id pub-id-type="doi">10.1128/mBio.00642-16</pub-id><pub-id pub-id-type="pmid">27486187</pub-id></citation>
</ref>
<ref id="B22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khanfar</surname> <given-names>H. S.</given-names></name> <name><surname>Bindayna</surname> <given-names>K. M.</given-names></name> <name><surname>Senok</surname> <given-names>A. C.</given-names></name> <name><surname>Botta</surname> <given-names>G. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Extended spectrum beta-lactamases (ESBL) in <italic>Escherichia coli</italic> and Klebsiella pneumoniae: trends in the hospital and community settings</article-title>. <source>J. Infect. Dev. Ctries.</source> <volume>3</volume>, <fpage>295</fpage>&#x02013;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.3855/jidc.127</pub-id><pub-id pub-id-type="pmid">19759493</pub-id></citation>
</ref>
<ref id="B23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kishii</surname> <given-names>R.</given-names></name> <name><surname>Takei</surname> <given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Relationship between the expression of ompF and quinolone resistance in <italic>Escherichia coli</italic></article-title>. <source>J. Infect. Chemother.</source> <volume>15</volume>, <fpage>361</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1007/s10156-009-0716-6</pub-id><pub-id pub-id-type="pmid">20012725</pub-id></citation>
</ref>
<ref id="B24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname> <given-names>M. E.</given-names></name> <name><surname>Loughman</surname> <given-names>J. A.</given-names></name> <name><surname>Hunstad</surname> <given-names>D. A.</given-names></name></person-group> (<year>2012</year>). <article-title>YbcL of uropathogenic <italic>Escherichia coli</italic> suppresses transepithelial neutrophil migration</article-title>. <source>Infect. Immun.</source> <volume>80</volume>, <fpage>4123</fpage>&#x02013;<lpage>4132</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00801-12</pub-id><pub-id pub-id-type="pmid">22966043</pub-id></citation>
</ref>
<ref id="B25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mysorekar</surname> <given-names>I. U.</given-names></name> <name><surname>Hultgren</surname> <given-names>S. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Mechanisms of uropathogenic <italic>Escherichia coli</italic> persistence and eradication from the urinary tract</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>103</volume>, <fpage>14170</fpage>&#x02013;<lpage>14175</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0602136103</pub-id><pub-id pub-id-type="pmid">16968784</pub-id></citation>
</ref>
<ref id="B26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onnberg</surname> <given-names>A.</given-names></name> <name><surname>Molling</surname> <given-names>P.</given-names></name> <name><surname>Zimmermann</surname> <given-names>J.</given-names></name> <name><surname>Soderquist</surname> <given-names>B.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular and phenotypic characterization of <italic>Escherichia coli</italic> and Klebsiella pneumoniae producing extended-spectrum beta-lactamases with focus on CTX-M in a low-endemic area in Sweden</article-title>. <source>APMIS</source> <volume>119</volume>, <fpage>287</fpage>&#x02013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0463.2011.02730.x</pub-id><pub-id pub-id-type="pmid">21492229</pub-id></citation>
</ref>
<ref id="B27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pichon</surname> <given-names>C.</given-names></name> <name><surname>Hechard</surname> <given-names>C.</given-names></name> <name><surname>Du Merle</surname> <given-names>L.</given-names></name> <name><surname>Chaudray</surname> <given-names>C.</given-names></name> <name><surname>Bonne</surname> <given-names>I.</given-names></name> <name><surname>Guadagnini</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Uropathogenic <italic>Escherichia coli</italic> AL511 requires flagellum to enter renal collecting duct cells</article-title>. <source>Cell Microbiol.</source> <volume>11</volume>, <fpage>616</fpage>&#x02013;<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2008.01278.x</pub-id><pub-id pub-id-type="pmid">19134121</pub-id></citation>
</ref>
<ref id="B28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitout</surname> <given-names>J. D.</given-names></name> <name><surname>Laupland</surname> <given-names>K. B.</given-names></name></person-group> (<year>2008</year>). <article-title>Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern</article-title>. <source>Lancet Infect. Dis.</source> <volume>8</volume>, <fpage>159</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(08)70041-0</pub-id><pub-id pub-id-type="pmid">18291338</pub-id></citation>
</ref>
<ref id="B29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ronald</surname> <given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>The etiology of urinary tract infection: traditional and emerging pathogens</article-title>. <source>Dis. Mon.</source> <volume>49</volume>, <fpage>71</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1067/mda.2003.8</pub-id><pub-id pub-id-type="pmid">12601338</pub-id></citation>
</ref>
<ref id="B30">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname> <given-names>V.</given-names></name> <name><surname>Ulett</surname> <given-names>G. C.</given-names></name> <name><surname>Schembri</surname> <given-names>M. A.</given-names></name> <name><surname>Klemm</surname> <given-names>P.</given-names></name></person-group> (<year>2006</year>). <article-title>The asymptomatic bacteriuria <italic>Escherichia coli</italic> strain 83972 outcompetes uropathogenic <italic>E. coli</italic> strains in human urine</article-title>. <source>Infect. Immun.</source> <volume>74</volume>, <fpage>615</fpage>&#x02013;<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.74.1.615-624.2006</pub-id><pub-id pub-id-type="pmid">16369018</pub-id></citation>
</ref>
<ref id="B31">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname> <given-names>D. A.</given-names></name> <name><surname>Hooton</surname> <given-names>T. M.</given-names></name> <name><surname>Stamm</surname> <given-names>W. E.</given-names></name> <name><surname>Humphrey</surname> <given-names>P. A.</given-names></name> <name><surname>Hultgren</surname> <given-names>S. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Detection of intracellular bacterial communities in human urinary tract infection</article-title>. <source>PLoS Med.</source> <volume>4</volume>:<fpage>e329</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.0040329</pub-id><pub-id pub-id-type="pmid">18092884</pub-id></citation>
</ref>
<ref id="B32">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smart</surname> <given-names>S. J.</given-names></name> <name><surname>Casale</surname> <given-names>T. B.</given-names></name></person-group> (<year>1994</year>). <article-title>Tnf-Alpha-Induced transendothelial neutrophil migration is Il-8 dependent</article-title>. <source>Am. J. Physiol.</source> <volume>266</volume>, <fpage>L238</fpage>&#x02013;<lpage>L245</lpage>. <pub-id pub-id-type="pmid">8166294</pub-id></citation>
</ref>
<ref id="B33">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>Q.</given-names></name> <name><surname>Guan</surname> <given-names>T.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name> <name><surname>Lv</surname> <given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Siderophore biosynthesis governs the virulence of uropathogenic <italic>Escherichia coli</italic> by coordinately modulating the differential metabolism</article-title>. <source>J. Proteome Res.</source> <volume>15</volume>, <fpage>1323</fpage>&#x02013;<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00061</pub-id><pub-id pub-id-type="pmid">26954697</pub-id></citation>
</ref>
<ref id="B34">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subashchandrabose</surname> <given-names>S.</given-names></name> <name><surname>Hazen</surname> <given-names>T. H.</given-names></name> <name><surname>Rasko</surname> <given-names>D. A.</given-names></name> <name><surname>Mobley</surname> <given-names>H. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Draft genome sequences of five recent human uropathogenic <italic>Escherichia coli</italic> isolates</article-title>. <source>Pathog Dis.</source> <volume>69</volume>, <fpage>66</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1111/2049-632X.12059</pub-id><pub-id pub-id-type="pmid">23821517</pub-id></citation>
</ref>
<ref id="B35">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subashchandrabose</surname> <given-names>S.</given-names></name> <name><surname>Mobley</surname> <given-names>H. L. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Virulence and fitness determinants of uropathogenic <italic>Escherichia coli</italic></article-title>. <source>Microbiol. Spectr.</source> <volume>3</volume>:<fpage>10</fpage>.1128/microbiolspec.UTI-0015-2012. <pub-id pub-id-type="doi">10.1128/microbiolspec.UTI-0015-2012</pub-id><pub-id pub-id-type="pmid">26350328</pub-id></citation>
</ref>
<ref id="B36">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tumbarello</surname> <given-names>M.</given-names></name> <name><surname>Sanguinetti</surname> <given-names>M.</given-names></name> <name><surname>Montuori</surname> <given-names>E.</given-names></name> <name><surname>Trecarichi</surname> <given-names>E. M.</given-names></name> <name><surname>Posteraro</surname> <given-names>B.</given-names></name> <name><surname>Fiori</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing enterobacteriaceae: Importance of inadequate initial antimicrobial treatment</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>51</volume>, <fpage>1987</fpage>&#x02013;<lpage>1994</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01509-06</pub-id><pub-id pub-id-type="pmid">17387156</pub-id></citation>
</ref>
<ref id="B37">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>X. B.</given-names></name> <name><surname>Tian</surname> <given-names>L. H.</given-names></name> <name><surname>Zou</surname> <given-names>H. J.</given-names></name> <name><surname>Wang</surname> <given-names>C. Y.</given-names></name> <name><surname>Yu</surname> <given-names>Z. Q.</given-names></name> <name><surname>Tang</surname> <given-names>C. H.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Outer membrane protein OmpW of <italic>Escherichia coli</italic> is required for resistance to phagocytosis</article-title>. <source>Res. Microbiol.</source> <volume>164</volume>, <fpage>848</fpage>&#x02013;<lpage>855</lpage>. <pub-id pub-id-type="doi">10.1016/j.resmic.2013.06.008</pub-id><pub-id pub-id-type="pmid">23811183</pub-id></citation>
</ref>
<ref id="B38">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname> <given-names>M.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Fischer</surname> <given-names>H.</given-names></name> <name><surname>Huang</surname> <given-names>W.</given-names></name> <name><surname>Lutay</surname> <given-names>N.</given-names></name> <name><surname>Cirl</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on <italic>Escherichia coli</italic> virulence</article-title>. <source>PLoS Pathog.</source> <volume>6</volume>:<fpage>e1001120</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1001120</pub-id><pub-id pub-id-type="pmid">20886104</pub-id></citation>
</ref>
</ref-list>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This project was financially supported by the Research Committee of &#x000D6;rebro County Council, Nyckelfonden, Swedish Society of Medicine and the Faculty of Medicine and Health at &#x000D6;rebro University.</p>
</fn>
</fn-group>
</back>
</article>